jazza personal page - To The Moon

jazza

No personal profile

561Follow

9Followers

10Topic

0Badge

04-06 02:36

Great article, would you like to share it?

Stock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs

04-06 02:35

Great article, would you like to share it?

Stock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs

04-06 02:26

Great article, would you like to share it?

Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts

04-06 01:12

Great article, would you like to share it?

Kazakhstan's central bank sells $748 million in foreign currency from national fund in March

04-06 01:12

Great article, would you like to share it?

Kazakhstan's central bank sells $748 million in foreign currency from national fund in March

04-06 01:12

Great article, would you like to share it?

BlackRock CEO: The Dollar Faces Risk of Losing Global Reserve Currency Status, Could Be Replaced by Bitcoin and Other Digital Assets

04-06 01:11

Great article, would you like to share it?

Fitch cuts China's foreign currency rating on rising debt, weakening finances

04-06 01:11

Great article, would you like to share it?

Peru's Central Bank Places Currency Swap of 700 Mln Soles

04-06 01:10

Great article, would you like to share it?

Sorry, the original content has been removed

04-06 01:10

Great article, would you like to share it?

Oneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Negative Impact of Msek 3.3 Since Beginning of Year

04-06 01:10

Great article, would you like to share it?

Sorry, the original content has been removed

04-06 01:09

Great article, would you like to share it?

Currency Rates Of Pulp and Paper Producing Countries

04-06 01:08

Great article, would you like to share it?

Chilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar

04-05

Great article, would you like to share it?

Tesla Launches Cheaper "Juniper" Model Y, Price $10K Below Launch Series

04-05

NZ STOCK MARKET QUOTES

Find out more here:NZ STOCK MARKET QUOTES null

NZ STOCK MARKET QUOTES

04-05

Great article, would you like to share it?

@TigerStars:Weekly Top Contributor (10 - 16 Feb): Congrats to these Tigers on winning $225 vouchers in total!

04-05

$COMMONWEALTH BANK OF AUSTRALIA(CBA.AU)$

04-05

Great article, would you like to share it?

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

04-05

$Roundhill Magnificent Seven ETF(MAGS)$

04-05

US Market 24H and Overnight Trading - Help - Tiger Brokers

Find out more here:US Market 24H and Overnight Trading - Help - Tiger Brokers

US Market 24H and Overnight Trading - Help - Tiger Brokers

Go to Tiger App to see more news

Invest in Global Markets with Tiger Brokers!

Open App

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4206112858455532","uuid":"4206112858455532","gmtCreate":1743009678032,"gmtModify":1743016505153,"name":"jazza","pinyin":"jazza","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":"https://static.tigerbbs.com/1c1eed764d9c7ff83dc093fbb9a96bc2","hatId":"shopping-00cc5c7d86fb60125608faae0e79884b","hatName":"Christmas frame","vip":1,"status":2,"fanSize":9,"headSize":561,"tweetSize":609,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":10,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006}],"userBadgeCount":2,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":421476703867240,"gmtCreate":1743906960514,"gmtModify":1743906962126,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421476703867240","repostId":"1189360887","repostType":2,"repost":{"id":"1189360887","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1743761949,"share":"https://ttm.financial/m/news/1189360887?lang=&edition=full_marsco","pubTime":"2025-04-04 18:19","market":"nz","language":"en","title":"Stock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=1189360887","media":"Stock Track","summary":"ProShares UltraPro QQQ , a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.At the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip an","content":"<p>ProShares UltraPro QQQ (TQQQ), a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.</p>\n\n<p>The tech-heavy Nasdaq 100 Stock Index has already shed $1.4 trillion in market capitalization following Thursday's slump, with the index down 16% over the past six weeks. Given TQQQ's triple-leveraged nature, it's particularly sensitive to these market movements, explaining its steep pre-market drop. The so-called \"Magnificent Seven\" tech stocks have been hit even harder, declining by 20% during the same period.</p>\n\n<p>At the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip and high-tech manufacturing, are facing levies of 54% and 32% respectively. Even emerging production bases like Vietnam and India are looking at taxes of at least 26%. This situation poses a significant challenge for major tech companies like Apple, Nvidia, and Broadcom, which rely heavily on overseas manufacturing and complex supply chains. The tariffs leave these companies with the difficult choice of raising prices or absorbing costs, both of which could negatively impact their financial performance and, consequently, their stock prices.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-04 18:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ProShares UltraPro QQQ (TQQQ), a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.</p>\n\n<p>The tech-heavy Nasdaq 100 Stock Index has already shed $1.4 trillion in market capitalization following Thursday's slump, with the index down 16% over the past six weeks. Given TQQQ's triple-leveraged nature, it's particularly sensitive to these market movements, explaining its steep pre-market drop. The so-called \"Magnificent Seven\" tech stocks have been hit even harder, declining by 20% during the same period.</p>\n\n<p>At the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip and high-tech manufacturing, are facing levies of 54% and 32% respectively. Even emerging production bases like Vietnam and India are looking at taxes of at least 26%. This situation poses a significant challenge for major tech companies like Apple, Nvidia, and Broadcom, which rely heavily on overseas manufacturing and complex supply chains. The tariffs leave these companies with the difficult choice of raising prices or absorbing costs, both of which could negatively impact their financial performance and, consequently, their stock prices.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189360887","content_text":"ProShares UltraPro QQQ (TQQQ), a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.\nThe tech-heavy Nasdaq 100 Stock Index has already shed $1.4 trillion in market capitalization following Thursday's slump, with the index down 16% over the past six weeks. Given TQQQ's triple-leveraged nature, it's particularly sensitive to these market movements, explaining its steep pre-market drop. The so-called \"Magnificent Seven\" tech stocks have been hit even harder, declining by 20% during the same period.\nAt the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip and high-tech manufacturing, are facing levies of 54% and 32% respectively. Even emerging production bases like Vietnam and India are looking at taxes of at least 26%. This situation poses a significant challenge for major tech companies like Apple, Nvidia, and Broadcom, which rely heavily on overseas manufacturing and complex supply chains. The tariffs leave these companies with the difficult choice of raising prices or absorbing costs, both of which could negatively impact their financial performance and, consequently, their stock prices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":3,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421476686463336,"gmtCreate":1743906956265,"gmtModify":1743906958668,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421476686463336","repostId":"1189360887","repostType":2,"repost":{"id":"1189360887","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1743761949,"share":"https://ttm.financial/m/news/1189360887?lang=&edition=full_marsco","pubTime":"2025-04-04 18:19","market":"nz","language":"en","title":"Stock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=1189360887","media":"Stock Track","summary":"ProShares UltraPro QQQ , a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.At the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip an","content":"<p>ProShares UltraPro QQQ (TQQQ), a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.</p>\n\n<p>The tech-heavy Nasdaq 100 Stock Index has already shed $1.4 trillion in market capitalization following Thursday's slump, with the index down 16% over the past six weeks. Given TQQQ's triple-leveraged nature, it's particularly sensitive to these market movements, explaining its steep pre-market drop. The so-called \"Magnificent Seven\" tech stocks have been hit even harder, declining by 20% during the same period.</p>\n\n<p>At the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip and high-tech manufacturing, are facing levies of 54% and 32% respectively. Even emerging production bases like Vietnam and India are looking at taxes of at least 26%. This situation poses a significant challenge for major tech companies like Apple, Nvidia, and Broadcom, which rely heavily on overseas manufacturing and complex supply chains. The tariffs leave these companies with the difficult choice of raising prices or absorbing costs, both of which could negatively impact their financial performance and, consequently, their stock prices.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TQQQ Plunges 5.01% Pre-Market as Tech Sector Reels from Trump's New Tariffs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-04 18:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ProShares UltraPro QQQ (TQQQ), a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.</p>\n\n<p>The tech-heavy Nasdaq 100 Stock Index has already shed $1.4 trillion in market capitalization following Thursday's slump, with the index down 16% over the past six weeks. Given TQQQ's triple-leveraged nature, it's particularly sensitive to these market movements, explaining its steep pre-market drop. The so-called \"Magnificent Seven\" tech stocks have been hit even harder, declining by 20% during the same period.</p>\n\n<p>At the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip and high-tech manufacturing, are facing levies of 54% and 32% respectively. Even emerging production bases like Vietnam and India are looking at taxes of at least 26%. This situation poses a significant challenge for major tech companies like Apple, Nvidia, and Broadcom, which rely heavily on overseas manufacturing and complex supply chains. The tariffs leave these companies with the difficult choice of raising prices or absorbing costs, both of which could negatively impact their financial performance and, consequently, their stock prices.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TQQQ":"纳指三倍做多ETF"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189360887","content_text":"ProShares UltraPro QQQ (TQQQ), a leveraged ETF that aims to deliver three times the daily performance of the Nasdaq-100 Index, plummeted 5.01% in pre-market trading on Friday. This sharp decline comes as the broader technology sector faces a significant selloff triggered by President Donald Trump's announcement of a new, harsh tariff regime.\nThe tech-heavy Nasdaq 100 Stock Index has already shed $1.4 trillion in market capitalization following Thursday's slump, with the index down 16% over the past six weeks. Given TQQQ's triple-leveraged nature, it's particularly sensitive to these market movements, explaining its steep pre-market drop. The so-called \"Magnificent Seven\" tech stocks have been hit even harder, declining by 20% during the same period.\nAt the heart of this tech sector turmoil are Trump's new tariffs, which are being described as the harshest in a century. China and Taiwan, global hubs for chip and high-tech manufacturing, are facing levies of 54% and 32% respectively. Even emerging production bases like Vietnam and India are looking at taxes of at least 26%. This situation poses a significant challenge for major tech companies like Apple, Nvidia, and Broadcom, which rely heavily on overseas manufacturing and complex supply chains. The tariffs leave these companies with the difficult choice of raising prices or absorbing costs, both of which could negatively impact their financial performance and, consequently, their stock prices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":49,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421377752830320,"gmtCreate":1743906374938,"gmtModify":1743906379224,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421377752830320","repostId":"2525790765","repostType":2,"repost":{"id":"2525790765","kind":"highlight","pubTimestamp":1743856969,"share":"https://ttm.financial/m/news/2525790765?lang=&edition=full_marsco","pubTime":"2025-04-05 20:42","market":"us","language":"en","title":"Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2525790765","media":"Simply Wall St.","summary":"Celebrations may be in order for Opus Genetics, Inc.  shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.Following the upgrade, the current consensus from Opus Genetics' three analysts is for revenues of US$17m in 2025 which - if met - would reflect a substantial 57% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 37% to US$0.80. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$13m and losses of US$0.99 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also redu","content":"<html><body><p>Celebrations may be in order for <strong>Opus Genetics, Inc.</strong> (NASDAQ:IRD) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. </p>\n<p>Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>\n<p> Following the upgrade, the current consensus from Opus Genetics' three analysts is for revenues of US$17m in 2025 which - if met - would reflect a substantial 57% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 37% to US$0.80. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$13m and losses of US$0.99 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. </p>\n<p><span> View our latest analysis for Opus Genetics </span></p>\n<figure>\n<img height=\"524\" src=\"https://s1.yimg.com/uu/api/res/1.2/9BVbQ8INzHFrR6T2FZHatA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/simply_wall_st__316/3af76177746778183c523a0e7e8fe369\" width=\"821\"/>\n<figcaption>\n  NasdaqCM:IRD Earnings and Revenue Growth April 5th 2025\n </figcaption>\n</figure>\n<p> Despite these upgrades, the analysts have not made any major changes to their price target of US$10.33, implying that their latest estimates don't have a long term impact on what they think the stock is worth. </p>\n<p> Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Opus Genetics'historical trends, as the 57% annualised revenue growth to the end of 2025 is roughly in line with the 52% annual revenue growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.2% per year. So it's pretty clear that Opus Genetics is forecast to grow substantially faster than its industry. </p>\n<h2>The Bottom Line </h2>\n<p> The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Opus Genetics is moving incrementally towards profitability. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. The lack of change in the price target is puzzling, but with a serious upgrade to this year's earnings expectations, it might be time to take another look at Opus Genetics. </p>\n<p> These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 4 potential flags with Opus Genetics, including major dilution from new stock issuance in the past year. You can learn more, and  discover the 3 other flags we've identified, for free on our platform here.  </p>\n<p> Another way to search for interesting companies that could be <strong> reaching an inflection point</strong> is to track whether management are buying or selling, with our <strong>free </strong>list of growing companies backed by insiders. </p>\n<p><strong>Have feedback on this article? Concerned about the content?</strong> <strong>Get in touch</strong><strong> with us directly.</strong><i> Alternatively, email editorial-team (at) simplywallst.com.</i><br/><br/><i>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</i><br/><br/></p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParty Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-05 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/party-time-brokers-just-made-124249859.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Celebrations may be in order for Opus Genetics, Inc. (NASDAQ:IRD) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly ...</p>\n\n<a href=\"https://finance.yahoo.com/news/party-time-brokers-just-made-124249859.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/party-time-brokers-just-made-124249859.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2525790765","content_text":"Celebrations may be in order for Opus Genetics, Inc. (NASDAQ:IRD) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. \nTrump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.\n Following the upgrade, the current consensus from Opus Genetics' three analysts is for revenues of US$17m in 2025 which - if met - would reflect a substantial 57% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 37% to US$0.80. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$13m and losses of US$0.99 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. \n View our latest analysis for Opus Genetics \n\n\n\n  NasdaqCM:IRD Earnings and Revenue Growth April 5th 2025\n \n\n Despite these upgrades, the analysts have not made any major changes to their price target of US$10.33, implying that their latest estimates don't have a long term impact on what they think the stock is worth. \n Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Opus Genetics'historical trends, as the 57% annualised revenue growth to the end of 2025 is roughly in line with the 52% annual revenue growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.2% per year. So it's pretty clear that Opus Genetics is forecast to grow substantially faster than its industry. \nThe Bottom Line \n The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Opus Genetics is moving incrementally towards profitability. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. The lack of change in the price target is puzzling, but with a serious upgrade to this year's earnings expectations, it might be time to take another look at Opus Genetics. \n These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 4 potential flags with Opus Genetics, including major dilution from new stock issuance in the past year. You can learn more, and  discover the 3 other flags we've identified, for free on our platform here.  \n Another way to search for interesting companies that could be  reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421360552235104,"gmtCreate":1743901971971,"gmtModify":1743901974258,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421360552235104","repostId":"2524137994","repostType":2,"repost":{"id":"2524137994","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1743485412,"share":"https://ttm.financial/m/news/2524137994?lang=&edition=full_marsco","pubTime":"2025-04-01 13:30","market":"nz","language":"en","title":"Kazakhstan's central bank sells $748 million in foreign currency from national fund in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2524137994","media":"Reuters","summary":"Kazakhstan's central bank sells $748 million in foreign currency from national fund in MarchALMATY, April 1  - Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April.  ","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kazakhstan's central bank sells $748 million in foreign currency from national fund in March</title></head><body><p><span>ALMATY, April 1 (Reuters)</span><span> - </span>Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April.</p><p> (Reporting by Mariya Gordeyeva; Writing by Anton Kolodyazhnyy; Editing by Christopher Cushing)</p><p> ((moscow.newsroom@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kazakhstan's central bank sells $748 million in foreign currency from national fund in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKazakhstan's central bank sells $748 million in foreign currency from national fund in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-01 13:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kazakhstan's central bank sells $748 million in foreign currency from national fund in March</title></head><body><p><span>ALMATY, April 1 (Reuters)</span><span> - </span>Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April.</p><p> (Reporting by Mariya Gordeyeva; Writing by Anton Kolodyazhnyy; Editing by Christopher Cushing)</p><p> ((moscow.newsroom@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nS8N3Q101T:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2524137994","content_text":"Kazakhstan's central bank sells $748 million in foreign currency from national fund in MarchALMATY, April 1 (Reuters) - Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April. (Reporting by Mariya Gordeyeva; Writing by Anton Kolodyazhnyy; Editing by Christopher Cushing) ((moscow.newsroom@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":13,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421359809634496,"gmtCreate":1743901967902,"gmtModify":1743901970049,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421359809634496","repostId":"2524137994","repostType":2,"repost":{"id":"2524137994","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1743485412,"share":"https://ttm.financial/m/news/2524137994?lang=&edition=full_marsco","pubTime":"2025-04-01 13:30","market":"nz","language":"en","title":"Kazakhstan's central bank sells $748 million in foreign currency from national fund in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2524137994","media":"Reuters","summary":"Kazakhstan's central bank sells $748 million in foreign currency from national fund in MarchALMATY, April 1  - Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April.  ","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kazakhstan's central bank sells $748 million in foreign currency from national fund in March</title></head><body><p><span>ALMATY, April 1 (Reuters)</span><span> - </span>Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April.</p><p> (Reporting by Mariya Gordeyeva; Writing by Anton Kolodyazhnyy; Editing by Christopher Cushing)</p><p> ((moscow.newsroom@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kazakhstan's central bank sells $748 million in foreign currency from national fund in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKazakhstan's central bank sells $748 million in foreign currency from national fund in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-01 13:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kazakhstan's central bank sells $748 million in foreign currency from national fund in March</title></head><body><p><span>ALMATY, April 1 (Reuters)</span><span> - </span>Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April.</p><p> (Reporting by Mariya Gordeyeva; Writing by Anton Kolodyazhnyy; Editing by Christopher Cushing)</p><p> ((moscow.newsroom@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nS8N3Q101T:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2524137994","content_text":"Kazakhstan's central bank sells $748 million in foreign currency from national fund in MarchALMATY, April 1 (Reuters) - Kazakhstan's central bank said on Tuesday that it sold $748 million worth of foreign currency from the national fund on the domestic market in March and plans to sell up to $1.05 billion in April. (Reporting by Mariya Gordeyeva; Writing by Anton Kolodyazhnyy; Editing by Christopher Cushing) ((moscow.newsroom@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421532454027288,"gmtCreate":1743901942958,"gmtModify":1743901944599,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421532454027288","repostId":"2523923549","repostType":2,"repost":{"id":"2523923549","kind":"highlight","pubTimestamp":1743430260,"share":"https://ttm.financial/m/news/2523923549?lang=&edition=full_marsco","pubTime":"2025-03-31 22:11","market":"hk","language":"en","title":"BlackRock CEO: The Dollar Faces Risk of Losing Global Reserve Currency Status, Could Be Replaced by Bitcoin and Other Digital Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2523923549","media":"Blockbeats","summary":"BlockBeats News, March 31st, according to Bitcoin Magazine, BlackRock CEO Larry Fink stated that the US dollar \"is at risk of losing\" its status as the global reserve currency and could be replaced by \"Bitcoin and other digital assets.\"","content":"<html><body><div><p>BlockBeats News, March 31st, according to Bitcoin Magazine, BlackRock CEO Larry Fink stated that the US dollar \"is at risk of losing\" its status as the global reserve currency and could be replaced by \"Bitcoin and other digital assets.\"</p></div></body></html>","source":"theblockbeats_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlackRock CEO: The Dollar Faces Risk of Losing Global Reserve Currency Status, Could Be Replaced by Bitcoin and Other Digital Assets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlackRock CEO: The Dollar Faces Risk of Losing Global Reserve Currency Status, Could Be Replaced by Bitcoin and Other Digital Assets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-31 22:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.theblockbeats.info//en/flash/287691><strong>Blockbeats</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BlockBeats News, March 31st, according to Bitcoin Magazine, BlackRock CEO Larry Fink stated that the US dollar \"is at risk of losing\" its status as the global reserve currency and could be replaced by...</p>\n\n<a href=\"https://www.theblockbeats.info//en/flash/287691\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"83042":"华夏比特币-R","03439":"嘉实比特币","BK4601":"加密货币现货ETF","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","BK4204":"教育服务","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BLK":"贝莱德","BK1611":"加密货币现货ETF","09439":"嘉实比特币-U","03008":"博时比特币","09008":"博时比特币-U","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4506":"内地教育股","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","03042":"华夏比特币","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU1509826696.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) INC B","BK4588":"碎股","09042":"华夏比特币-U","BK4552":"Archegos爆仓风波概念","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4503":"景林资产持仓","LU0772969993.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) ACC","LU0742537680.HKD":"FIDELITY GLOBAL DIVIDEND \"A \" (HKD) INC","BK4510":"在线教育","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU1481011911.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USDHDG) INC","GOTU":"高途","BK4504":"桥水持仓","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD"},"source_url":"https://www.theblockbeats.info//en/flash/287691","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2523923549","content_text":"BlockBeats News, March 31st, according to Bitcoin Magazine, BlackRock CEO Larry Fink stated that the US dollar \"is at risk of losing\" its status as the global reserve currency and could be replaced by \"Bitcoin and other digital assets.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421487037403216,"gmtCreate":1743901916054,"gmtModify":1743901918532,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421487037403216","repostId":"2524257471","repostType":2,"repost":{"id":"2524257471","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1743686904,"share":"https://ttm.financial/m/news/2524257471?lang=&edition=full_marsco","pubTime":"2025-04-03 21:28","market":"nz","language":"en","title":"Fitch cuts China's foreign currency rating on rising debt, weakening finances","url":"https://stock-news.laohu8.com/highlight/detail?id=2524257471","media":"Reuters","summary":"UPDATE 1-Fitch cuts China's foreign currency rating on rising debt, weakening financesAdds details on trade tensions in paragraphs 2 to 4","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-Fitch cuts China's foreign currency rating on rising debt, weakening finances</title></head><body><p>Adds details on trade tensions in paragraphs 2 to 4</p><p>\n<span>April 3 (Reuters)</span><span> - </span>Global ratings agency Fitch on Thursday downgraded China's long-term foreign currency credit rating to 'A' from 'A+', on  expectations of weak public finances and rapidly rising debt.</p><p><span>The latest U.S. reciprocal tariffs have not been incorporated in the forecast, Fitch said, adding that there is uncertainty about their impact.</span></p><p>The government's debt-to-GDP ratio is expected to rise further over the next few years due to trade tensions with the U.S., subdued domestic demand and deflationary pressure, the rating agency said.</p><p>It expects China to be affected by a broader tariff-induced global slowdown, despite the country appearing more resilient to direct U.S. tariffs compared to President Donald Trump's first term.</p><p>China's <span>yuan</span> dropped to its lowest level in seven weeks and stock markets slumped on Thursday after Trump unveiled a sweeping set of reciprocal tariffs that were particularly heavy on China and its main trading partners.</p><p> (Reporting by Aatrayee Chatterjee in Bengaluru; Editing by Leroy Leo)</p><p> ((Aatrayee.Chatterjee@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fitch cuts China's foreign currency rating on rising debt, weakening finances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFitch cuts China's foreign currency rating on rising debt, weakening finances\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-03 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-Fitch cuts China's foreign currency rating on rising debt, weakening finances</title></head><body><p>Adds details on trade tensions in paragraphs 2 to 4</p><p>\n<span>April 3 (Reuters)</span><span> - </span>Global ratings agency Fitch on Thursday downgraded China's long-term foreign currency credit rating to 'A' from 'A+', on  expectations of weak public finances and rapidly rising debt.</p><p><span>The latest U.S. reciprocal tariffs have not been incorporated in the forecast, Fitch said, adding that there is uncertainty about their impact.</span></p><p>The government's debt-to-GDP ratio is expected to rise further over the next few years due to trade tensions with the U.S., subdued domestic demand and deflationary pressure, the rating agency said.</p><p>It expects China to be affected by a broader tariff-induced global slowdown, despite the country appearing more resilient to direct U.S. tariffs compared to President Donald Trump's first term.</p><p>China's <span>yuan</span> dropped to its lowest level in seven weeks and stock markets slumped on Thursday after Trump unveiled a sweeping set of reciprocal tariffs that were particularly heavy on China and its main trading partners.</p><p> (Reporting by Aatrayee Chatterjee in Bengaluru; Editing by Leroy Leo)</p><p> ((Aatrayee.Chatterjee@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nL3N3QH186:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2524257471","content_text":"UPDATE 1-Fitch cuts China's foreign currency rating on rising debt, weakening financesAdds details on trade tensions in paragraphs 2 to 4\nApril 3 (Reuters) - Global ratings agency Fitch on Thursday downgraded China's long-term foreign currency credit rating to 'A' from 'A+', on  expectations of weak public finances and rapidly rising debt.The latest U.S. reciprocal tariffs have not been incorporated in the forecast, Fitch said, adding that there is uncertainty about their impact.The government's debt-to-GDP ratio is expected to rise further over the next few years due to trade tensions with the U.S., subdued domestic demand and deflationary pressure, the rating agency said.It expects China to be affected by a broader tariff-induced global slowdown, despite the country appearing more resilient to direct U.S. tariffs compared to President Donald Trump's first term.China's yuan dropped to its lowest level in seven weeks and stock markets slumped on Thursday after Trump unveiled a sweeping set of reciprocal tariffs that were particularly heavy on China and its main trading partners. (Reporting by Aatrayee Chatterjee in Bengaluru; Editing by Leroy Leo) ((Aatrayee.Chatterjee@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421446103347240,"gmtCreate":1743901878249,"gmtModify":1743901880390,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421446103347240","repostId":"2524292617","repostType":2,"repost":{"id":"2524292617","kind":"live","pubTimestamp":1743705681,"share":"https://ttm.financial/m/news/2524292617?lang=&edition=full_marsco","pubTime":"2025-04-04 02:41","market":"us","language":"en","title":"Peru's Central Bank Places Currency Swap of 700 Mln Soles","url":"https://stock-news.laohu8.com/highlight/detail?id=2524292617","media":"THOMSON REUTERS","summary":"Peru's Central Bank Places Currency Swap of 700 Mln Soles","content":"<html><body><p>Peru's Central Bank Places Currency Swap of 700 Mln Soles</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peru's Central Bank Places Currency Swap of 700 Mln Soles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeru's Central Bank Places Currency Swap of 700 Mln Soles\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-04 02:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nS0N3LX09A:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Peru's Central Bank Places Currency Swap of 700 Mln Soles</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nS0N3LX09A:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nS0N3LX09A:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2524292617","content_text":"Peru's Central Bank Places Currency Swap of 700 Mln Soles","news_type":1},"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421554532614472,"gmtCreate":1743901849791,"gmtModify":1743901851888,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421554532614472","repostId":"2524105002","repostType":2,"isVote":1,"tweetType":1,"viewCount":20,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421359151669552,"gmtCreate":1743901829234,"gmtModify":1743901831472,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421359151669552","repostId":"2524722710","repostType":2,"repost":{"id":"2524722710","kind":"live","pubTimestamp":1743746448,"share":"https://ttm.financial/m/news/2524722710?lang=&edition=full_marsco","pubTime":"2025-04-04 14:00","market":"us","language":"en","title":"Oneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Negative Impact of Msek 3.3 Since Beginning of Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2524722710","media":"THOMSON REUTERS","summary":"Oneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Neg","content":"<html><body><p>Oneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Negative Impact of Msek 3.3 Since Beginning of Year</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Negative Impact of Msek 3.3 Since Beginning of Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Negative Impact of Msek 3.3 Since Beginning of Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-04 14:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QH1I0:2><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Negative Impact of Msek 3.3 Since Beginning of Year</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QH1I0:2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QH1I0:2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2524722710","content_text":"Oneflow Ab - Currency Effects Have Had a Negative Impact of Msek 1.7 Since End of February and a Negative Impact of Msek 3.3 Since Beginning of Year","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421455582552424,"gmtCreate":1743901803943,"gmtModify":1743901806152,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421455582552424","repostId":"2524768502","repostType":2,"isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421359021891888,"gmtCreate":1743901797550,"gmtModify":1743901799818,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421359021891888","repostId":"2524768502","repostType":2,"repost":{"id":"2524768502","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1743753900,"share":"https://ttm.financial/m/news/2524768502?lang=&edition=full_marsco","pubTime":"2025-04-04 16:05","market":"sg","language":"en","title":"Currency Rates Of Pulp and Paper Producing Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2524768502","media":"Dow Jones","summary":"Copyright (c) 2025 Dow Jones & Company, Inc.","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre><table><tbody><tr><td></td><td>Current</td><td>Prior </td><td></td></tr><tr><td>Argentina (Peso)</td><td>ARS</td><td>1074.34081</td><td>1072.73771 </td></tr><tr><td>Australia (Dollar)</td><td>AUD</td><td>1.61031</td><td>1.58479 </td></tr><tr><td>Brazil (Real)</td><td>BRL</td><td>5.64670</td><td>5.68180 </td></tr><tr><td>Canada (Dollar)</td><td>CAD</td><td>1.41545</td><td>1.41555 </td></tr><tr><td>China (Yuan)</td><td>CNY</td><td>7.28160</td><td>7.30200 </td></tr><tr><td>European Union (Euro)</td><td>EUR</td><td>0.90955</td><td>0.91087 </td></tr><tr><td>India (Rupee)</td><td>INR</td><td>85.23250</td><td>85.52500 </td></tr><tr><td>Indonesia (Rupiah)</td><td>IDR</td><td>16745.00000</td><td>16727.00000 </td></tr><tr><td>Japan (Yen)</td><td>JPY</td><td>146.38200</td><td>147.29200 </td></tr><tr><td>Korea, South (Won)</td><td>KRW</td><td>1443.79000</td><td>1463.69000 </td></tr><tr><td>Mexico (Peso)</td><td>MXN</td><td>20.10550</td><td>20.11910 </td></tr><tr><td>New Zealand (Dollar)</td><td>NZD</td><td>1.75840</td><td>1.73280 </td></tr><tr><td>Norway (Krone)</td><td>NOK</td><td>10.51720</td><td>10.34380 </td></tr><tr><td>Poland (Zloty)</td><td>PLN</td><td>3.85205</td><td>3.80985 </td></tr><tr><td>South Africa (Rand)</td><td>ZAR</td><td>19.02370</td><td>18.86120 </td></tr><tr><td>Sweden (Krona)</td><td>SEK</td><td>9.90990</td><td>9.75650 </td></tr><tr><td>Switzerland (Franc)</td><td>CHF</td><td>0.85520</td><td>0.86830 </td></tr><tr><td>Taiwan (Dollar)</td><td>TWD</td><td>32.99260</td><td>33.22250 </td></tr><tr><td>Thailand (Baht)</td><td>THB</td><td>34.17000</td><td>34.31000 </td></tr><tr><td>Turkey (New Lira)</td><td>TRY</td><td>38.01050</td><td>37.94650 </td></tr><tr><td></td><td>United Kingdom (Pound Sterling) GBP</td><td>0.76911</td><td>0.76115 </td></tr><tr><td>All currencies are quoted in units of currency per U.S. dollar. </td><td></td><td></td><td></td></tr><tr><td>Source: Tullett Prebon. </td><td></td><td></td><td></td></tr></tbody></table></pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 04, 2025 04:05 ET (08:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Currency Rates Of Pulp and Paper Producing Countries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCurrency Rates Of Pulp and Paper Producing Countries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-04 16:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre><table><tbody><tr><td></td><td>Current</td><td>Prior </td><td></td></tr><tr><td>Argentina (Peso)</td><td>ARS</td><td>1074.34081</td><td>1072.73771 </td></tr><tr><td>Australia (Dollar)</td><td>AUD</td><td>1.61031</td><td>1.58479 </td></tr><tr><td>Brazil (Real)</td><td>BRL</td><td>5.64670</td><td>5.68180 </td></tr><tr><td>Canada (Dollar)</td><td>CAD</td><td>1.41545</td><td>1.41555 </td></tr><tr><td>China (Yuan)</td><td>CNY</td><td>7.28160</td><td>7.30200 </td></tr><tr><td>European Union (Euro)</td><td>EUR</td><td>0.90955</td><td>0.91087 </td></tr><tr><td>India (Rupee)</td><td>INR</td><td>85.23250</td><td>85.52500 </td></tr><tr><td>Indonesia (Rupiah)</td><td>IDR</td><td>16745.00000</td><td>16727.00000 </td></tr><tr><td>Japan (Yen)</td><td>JPY</td><td>146.38200</td><td>147.29200 </td></tr><tr><td>Korea, South (Won)</td><td>KRW</td><td>1443.79000</td><td>1463.69000 </td></tr><tr><td>Mexico (Peso)</td><td>MXN</td><td>20.10550</td><td>20.11910 </td></tr><tr><td>New Zealand (Dollar)</td><td>NZD</td><td>1.75840</td><td>1.73280 </td></tr><tr><td>Norway (Krone)</td><td>NOK</td><td>10.51720</td><td>10.34380 </td></tr><tr><td>Poland (Zloty)</td><td>PLN</td><td>3.85205</td><td>3.80985 </td></tr><tr><td>South Africa (Rand)</td><td>ZAR</td><td>19.02370</td><td>18.86120 </td></tr><tr><td>Sweden (Krona)</td><td>SEK</td><td>9.90990</td><td>9.75650 </td></tr><tr><td>Switzerland (Franc)</td><td>CHF</td><td>0.85520</td><td>0.86830 </td></tr><tr><td>Taiwan (Dollar)</td><td>TWD</td><td>32.99260</td><td>33.22250 </td></tr><tr><td>Thailand (Baht)</td><td>THB</td><td>34.17000</td><td>34.31000 </td></tr><tr><td>Turkey (New Lira)</td><td>TRY</td><td>38.01050</td><td>37.94650 </td></tr><tr><td></td><td>United Kingdom (Pound Sterling) GBP</td><td>0.76911</td><td>0.76115 </td></tr><tr><td>All currencies are quoted in units of currency per U.S. dollar. </td><td></td><td></td><td></td></tr><tr><td>Source: Tullett Prebon. </td><td></td><td></td><td></td></tr></tbody></table></pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 04, 2025 04:05 ET (08:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2524768502","content_text":"CurrentPrior Argentina (Peso)ARS1074.340811072.73771 Australia (Dollar)AUD1.610311.58479 Brazil (Real)BRL5.646705.68180 Canada (Dollar)CAD1.415451.41555 China (Yuan)CNY7.281607.30200 European Union (Euro)EUR0.909550.91087 India (Rupee)INR85.2325085.52500 Indonesia (Rupiah)IDR16745.0000016727.00000 Japan (Yen)JPY146.38200147.29200 Korea, South (Won)KRW1443.790001463.69000 Mexico (Peso)MXN20.1055020.11910 New Zealand (Dollar)NZD1.758401.73280 Norway (Krone)NOK10.5172010.34380 Poland (Zloty)PLN3.852053.80985 South Africa (Rand)ZAR19.0237018.86120 Sweden (Krona)SEK9.909909.75650 Switzerland (Franc)CHF0.855200.86830 Taiwan (Dollar)TWD32.9926033.22250 Thailand (Baht)THB34.1700034.31000 Turkey (New Lira)TRY38.0105037.94650 United Kingdom (Pound Sterling) GBP0.769110.76115 All currencies are quoted in units of currency per U.S. dollar. Source: Tullett Prebon. \n\n  (END) Dow Jones Newswires\n\n\n  April 04, 2025 04:05 ET (08:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421357962863016,"gmtCreate":1743901710027,"gmtModify":1743901713832,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421357962863016","repostId":"2525738660","repostType":2,"repost":{"id":"2525738660","kind":"live","pubTimestamp":1743784533,"share":"https://ttm.financial/m/news/2525738660?lang=&edition=full_marsco","pubTime":"2025-04-05 00:35","market":"nz","language":"en","title":"Chilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar","url":"https://stock-news.laohu8.com/highlight/detail?id=2525738660","media":"THOMSON REUTERS","summary":"Chilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar","content":"<html><body><p>Chilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-05 00:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nS0N3Q0037:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nS0N3Q0037:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nS0N3Q0037:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2525738660","content_text":"Chilean Peso Currency Closes -3.37%, at 979.80/980.10 Pesos per Dollar","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421129336295640,"gmtCreate":1743845426882,"gmtModify":1743845428599,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421129336295640","repostId":"1102744300","repostType":4,"repost":{"id":"1102744300","kind":"news","pubTimestamp":1743823200,"share":"https://ttm.financial/m/news/1102744300?lang=&edition=full_marsco","pubTime":"2025-04-05 11:20","market":"us","language":"en","title":"Tesla Launches Cheaper \"Juniper\" Model Y, Price $10K Below Launch Series","url":"https://stock-news.laohu8.com/highlight/detail?id=1102744300","media":"Forbes","summary":"Tesla has introduced a new trim of the 2026 Long-Range All-Wheel Drive Model Y, priced $10,000 below the Launch series, which no longer appears on the order page.The Long-Range AWD is $49,990, exactly","content":"<html><head></head><body><p>Tesla has introduced a new trim of the 2026 Long-Range All-Wheel Drive Model Y, priced $10,000 below the Launch series, which no longer appears on the order page.</p><p style=\"text-align: start;\">The Long-Range AWD is $49,990, exactly $10,000 less than the Launch series, which was priced at $59,990. The lower-priced version has 327 miles of rated EPA range and does 0-60 in 4.6 seconds with a top speed of 125 MPH, like the Launch series. With the $7,500 federal tax credit, the price is $41,490.</p><p style=\"text-align: start;\">Tesla is also expected to offer an even less expensive Rear-Wheel Drive Model Y but that has yet to appear on the order page.</p><p style=\"text-align: start;\">The Launch series debuted in January and was the only version of the new Model Y —sometimes referred to by its erstwhile codename of “Juniper” – available to order until now. That Launch version included Full Self Driving ($8,000 value) and other features like a tow hitch. The new AWD version does not roll those features into the price and must be ordered separately.</p><p style=\"text-align: start;\">The prior-generation of the Model Y has disappeared from the order and the inventory page and is only available in the used market. That legacy version of the Long-Range AWD was priced at $48,990.</p><p>Earlier this week, Tesla reported that deliveries fell to 336,681 vehicles in the first quarter, a 13% decline from a year ago when deliveries were 386,810. Tesla’s stock has also been clobbered, as of Friday afternoon falling more than 40 percent since the beginning of the year. Protests at Tesla stores over CEO Elon Musk’s role in the Trump Administration have contributed to slumping consumer sentiment.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/e3946370b394a445d4c806ad3ba4b86b\" alt=\"Updated Model Y starts at $41,490 with the federal tax credit.\" title=\"Updated Model Y starts at $41,490 with the federal tax credit.\" tg-width=\"959\" tg-height=\"648\"/><span>Updated Model Y starts at $41,490 with the federal tax credit.</span></p><h2 id=\"id_3821215898\" style=\"text-align: start;\">A low-cost Model Y is also coming</h2><p style=\"text-align: start;\">Tesla will make a lower-cost version of its Model Y in Shanghai, according to reports. The low-cost version of the Y is aimed at helping the company regain market share in the highly competitive Chinese market.</p><p>Tesla is developing the model under a project codenamed &#34;E41&#34; and will build it using existing production lines, according to Reuters. Volume production will begin in 2026, the report said. The new version is expected to cost around 20% less to build than the current Model Y.</p></body></html>","source":"fors","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Launches Cheaper \"Juniper\" Model Y, Price $10K Below Launch Series</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Launches Cheaper \"Juniper\" Model Y, Price $10K Below Launch Series\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-05 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.forbes.com/sites/brookecrothers/2025/04/04/tesla-launches-cheaper-juniper-model-y-price-10k-below-launch-series/><strong>Forbes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla has introduced a new trim of the 2026 Long-Range All-Wheel Drive Model Y, priced $10,000 below the Launch series, which no longer appears on the order page.The Long-Range AWD is $49,990, exactly...</p>\n\n<a href=\"https://www.forbes.com/sites/brookecrothers/2025/04/04/tesla-launches-cheaper-juniper-model-y-price-10k-below-launch-series/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.forbes.com/sites/brookecrothers/2025/04/04/tesla-launches-cheaper-juniper-model-y-price-10k-below-launch-series/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102744300","content_text":"Tesla has introduced a new trim of the 2026 Long-Range All-Wheel Drive Model Y, priced $10,000 below the Launch series, which no longer appears on the order page.The Long-Range AWD is $49,990, exactly $10,000 less than the Launch series, which was priced at $59,990. The lower-priced version has 327 miles of rated EPA range and does 0-60 in 4.6 seconds with a top speed of 125 MPH, like the Launch series. With the $7,500 federal tax credit, the price is $41,490.Tesla is also expected to offer an even less expensive Rear-Wheel Drive Model Y but that has yet to appear on the order page.The Launch series debuted in January and was the only version of the new Model Y —sometimes referred to by its erstwhile codename of “Juniper” – available to order until now. That Launch version included Full Self Driving ($8,000 value) and other features like a tow hitch. The new AWD version does not roll those features into the price and must be ordered separately.The prior-generation of the Model Y has disappeared from the order and the inventory page and is only available in the used market. That legacy version of the Long-Range AWD was priced at $48,990.Earlier this week, Tesla reported that deliveries fell to 336,681 vehicles in the first quarter, a 13% decline from a year ago when deliveries were 386,810. Tesla’s stock has also been clobbered, as of Friday afternoon falling more than 40 percent since the beginning of the year. Protests at Tesla stores over CEO Elon Musk’s role in the Trump Administration have contributed to slumping consumer sentiment.Updated Model Y starts at $41,490 with the federal tax credit.A low-cost Model Y is also comingTesla will make a lower-cost version of its Model Y in Shanghai, according to reports. The low-cost version of the Y is aimed at helping the company regain market share in the highly competitive Chinese market.Tesla is developing the model under a project codenamed \"E41\" and will build it using existing production lines, according to Reuters. Volume production will begin in 2026, the report said. The new version is expected to cost around 20% less to build than the current Model Y.","news_type":1},"isVote":1,"tweetType":1,"viewCount":57,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421233960759576,"gmtCreate":1743845341502,"gmtModify":1743845346990,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"NZ STOCK MARKET QUOTES","htmlText":"Find out more here:<a href=\"https://tigr.link/s/50Ap8Nz\">NZ STOCK MARKET QUOTES</a> null","listText":"Find out more here:<a href=\"https://tigr.link/s/50Ap8Nz\">NZ STOCK MARKET QUOTES</a> null","text":"Find out more here:NZ STOCK MARKET QUOTES null","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421233960759576","isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421244626927816,"gmtCreate":1743845266966,"gmtModify":1743845268653,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421244626927816","repostId":"404514714648672","repostType":1,"repost":{"id":404514714648672,"gmtCreate":1739762102666,"gmtModify":1739765700926,"author":{"id":"9000000000000149","authorId":"9000000000000149","name":"TigerStars","avatar":"https://static.tigerbbs.com/e0b93d50cf0df54ce7b1b746f78db36c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000149","idStr":"9000000000000149"},"themes":[],"title":"Weekly Top Contributor (10 - 16 Feb): Congrats to these Tigers on winning $225 vouchers in total!","htmlText":"🌟 Welcome to our \"Top Contributor\" Awards Program! 🌟Congratulations to the outstanding contributors who made last week unforgettable! You are the heartbeat of our community, and your dedication shines bright.From 10 Feb - 16 FebWeekly Top Contributor ($25 stock voucher):<a href=\"https://ttm.financial/U/4185413129326452\">@Mickey082024</a> <a href=\"https://ttm.financial/U/3572212908677301\">@TigerOptions</a> <a href=\"https://ttm.financial/U/4177263596677932\">@Bullaroo</a> Weekly Top Contributor ($15 stock voucher): <a href=\"https://ttm.financial/U/4116373681054822\">@The Investing Iguana</a> <a href=\"https://ttm.financial/U/3570103090255456\">@JC888</a> <a href=\"https://ttm.financial/U/4102123614530830\">@nerdbull1669</a> <a href=\"https://ttm.financial/U/3559581955535845\">@koolgal</a>","listText":"🌟 Welcome to our \"Top Contributor\" Awards Program! 🌟Congratulations to the outstanding contributors who made last week unforgettable! You are the heartbeat of our community, and your dedication shines bright.From 10 Feb - 16 FebWeekly Top Contributor ($25 stock voucher):<a href=\"https://ttm.financial/U/4185413129326452\">@Mickey082024</a> <a href=\"https://ttm.financial/U/3572212908677301\">@TigerOptions</a> <a href=\"https://ttm.financial/U/4177263596677932\">@Bullaroo</a> Weekly Top Contributor ($15 stock voucher): <a href=\"https://ttm.financial/U/4116373681054822\">@The Investing Iguana</a> <a href=\"https://ttm.financial/U/3570103090255456\">@JC888</a> <a href=\"https://ttm.financial/U/4102123614530830\">@nerdbull1669</a> <a href=\"https://ttm.financial/U/3559581955535845\">@koolgal</a>","text":"🌟 Welcome to our \"Top Contributor\" Awards Program! 🌟Congratulations to the outstanding contributors who made last week unforgettable! You are the heartbeat of our community, and your dedication shines bright.From 10 Feb - 16 FebWeekly Top Contributor ($25 stock voucher):@Mickey082024 @TigerOptions @Bullaroo Weekly Top Contributor ($15 stock voucher): @The Investing Iguana @JC888 @nerdbull1669 @koolgal","images":[{"img":"https://community-static.tradeup.com/news/4b4fd36333edd2218fd5f5c6544d1e5b"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/404514714648672","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421302412587360,"gmtCreate":1743845222028,"gmtModify":1743845401418,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CBA.AU\">$COMMONWEALTH BANK OF AUSTRALIA(CBA.AU)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/CBA.AU\">$COMMONWEALTH BANK OF AUSTRALIA(CBA.AU)$&nbsp;</a>&nbsp;","text":"$COMMONWEALTH BANK OF AUSTRALIA(CBA.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421302412587360","isVote":1,"tweetType":1,"viewCount":20,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421125527933176,"gmtCreate":1743845021558,"gmtModify":1743845026120,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421125527933176","repostId":"2522837332","repostType":2,"repost":{"id":"2522837332","kind":"highlight","pubTimestamp":1742943720,"share":"https://ttm.financial/m/news/2522837332?lang=&edition=full_marsco","pubTime":"2025-03-26 07:02","market":"us","language":"en","title":"New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837332","media":"Business Wire","summary":"SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity. WILMINGTON, Del., March 25, 2025----New study results presented at the European Lung Cancer Congress  2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO , as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated  non-small cell lung cancer . Highlights include:. LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy  .SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with high levels of MET overexpression and/or amplification following disease progression on 1st-line TAGRISSO (#2O).FLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced EGFRm NSCLC .Professor Virginia Harrison, EGFR Positive UK, said: \"For people undergoin","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"286\" src=\"https://s.yimg.com/uu/api/res/1.2/ReAyKIjMiIQ4oWQFL_uVmQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/f7611870b5dd8b1b818e165bd035d813\" title=\"\" width=\"1181\"/>\n<figcaption></figcaption>\n</figure>\n<p><b><i>In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting</i></b></p>\n<p><b><i>SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to</i></b> <b><i>TAGRISSO upon disease progression demonstrates strong clinical activity</i></b></p>\n<p><b>WILMINGTON, Del., March 25, 2025</b>--(BUSINESS WIRE)--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO<sup>®</sup> (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (<i>EGFR</i>m) non-small cell lung cancer (NSCLC). Highlights include:</p>\n<ul>\n<li>LAURA Phase III trial of TAGRISSO in unresectable, Stage III <i>EGFR</i>m NSCLC after chemoradiotherapy (CRT) (LBA4).</li>\n<li>SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced <i>EGFR</i>m NSCLC with high levels of <i>MET</i> overexpression and/or amplification following disease progression on 1st-line TAGRISSO (#2O).</li>\n<li>ORCHARD Phase II platform trial of TAGRISSO plus datopotamab deruxtecan-dlnk in advanced <i>EGFR</i>m NSCLC following disease progression on 1st-line TAGRISSO (#1O).</li>\n<li>FLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced <i>EGFR</i>m NSCLC (#53P).</li>\n</ul>\n<p>Myung-Ju Ahn, MD, PhD, Professor of Hemato-Oncology at the Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, said: \"A critical goal in treating every patient with lung cancer is to not only extend a patient's life but also maintain quality of life while on treatment. The continued overall survival trend seen here at ELCC in the unresectable Stage III setting and the promising data for combinations that can address progression in the advanced setting, together reinforce osimertinib as an effective, safe and convenient treatment for patients with <i>EGFR</i>-mutated lung cancer across stages and lines of treatment.\"</p>\n<p>Susan Galbraith, Executive Vice President, Oncology Hematology R&amp;D, AstraZeneca, said: \"Having now treated more than one million patients around the world, TAGRISSO has repeatedly transformed expectations for patients with <i>EGFR</i>-mutated lung cancer by not only extending survival but also showing it is possible to maintain quality of life during cancer treatment. The breadth of data at ELCC reinforce TAGRISSO as the backbone therapy for patients with this disease and show that adding savolitinib or datopotamab deruxtecan-dlnk at the time of disease progression can help prolong patients’ responses to treatment.\"</p>\n<p>Professor Virginia Harrison, EGFR Positive UK, said: \"For people undergoing treatment for lung cancer, maintaining quality of life is so important, but it can be challenging. The development of simple and effective treatment regimens that minimize negative side effects can make a huge difference. We are excited to see this progress for patients with <i>EGFR</i>-mutated lung cancer, where there is still significant unmet need.\"</p>\n<p><b>TAGRISSO continued to demonstrate encouraging overall survival (OS) trend in unresectable, Stage III setting in LAURA trial<br/></b>Updated results from the LAURA Phase III trial showed an improved trend towards OS benefit with TAGRISSO compared to placebo in patients with unresectable, Stage III <i>EGFR</i>m NSCLC (hazard ratio [HR] 0.67; 95% confidence interval [CI] 0.40, 1.14, maturity 31%). Median OS was 58.8 months (95% CI 54.1, not calculable [NC]) in patients treated with TAGRISSO<i> </i>versus 54.1 months with placebo (95% CI 42.1, NC), despite 78% of patients on placebo receiving subsequent treatment with TAGRISSO<i> </i>upon progression. The trial will continue to assess OS as a key secondary endpoint at the final analysis.</p>\n<p>TAGRISSO previously demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS). These results were published in <i>The New England Journal of Medicine</i> and formed the basis for regulatory approvals around the world including in the US, EU and China.</p>\n<p>Safety results and discontinuation rates due to adverse events (AEs) were as expected and no new safety concerns were identified.</p>\n<p><b>TAGRISSO plus savolitinib</b> <b>showed durable response rates in lung cancer patients with high levels of <i>MET</i> overexpression and/or amplification whose disease progressed on 1st-line TAGRISSO in SAVANNAH trial<br/></b>Results from the SAVANNAH Phase II trial showed TAGRISSO plus savolitinib (300 mg twice-daily [BID]) demonstrated a clinically meaningful and durable objective response rate (ORR) in patients with <i>EGFR</i>m NSCLC with high levels of <i>MET</i> overexpression and/or amplification whose disease progressed on treatment with 1st-line TAGRISSO. Among patients screened for enrollment in SAVANNAH, an estimated 62% had tumors with <i>MET</i> overexpression and/or amplification, and approximately 34% met the defined high <i>MET</i> level cut-off.</p>\n<p>TAGRISSO plus savolitinib demonstrated a confirmed ORR of 56% (95% CI 45-67%), with a median duration of response (DoR) of 7.1 months (95% CI 5.6-9.6). Median PFS (mPFS) was 7.4 months (95% CI 5.5-7.6).</p>\n<p>Safety results and discontinuation rates due to AEs were consistent with the established profiles of each medicine and no new safety concerns were reported. In all patients treated with TAGRISSO plus savolitinib (300 mg BID), Grade 3 or higher AEs occurred in 57% of patients.</p>\n<p>Savolitinib is an oral, potent and highly selective <i>MET</i> tyrosine kinase inhibitor (TKI) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, TAGRISSO plus savolitinib received Fast Track designation from the Food and Drug Administration (FDA) in this setting.</p>\n<p><b>TAGRISSO plus datopotamab deruxtecan-dlnk<i> </i>showed encouraging response rates in patients whose disease progressed on 1st-line TAGRISSO in ORCHARD trial<br/></b>First results from the TAGRISSO plus datopotamab deruxtecan-dlnk module of the ORCHARD Phase II platform trial showed the combination demonstrated promising efficacy and manageable safety in patients with advanced <i>EGFR</i>m NSCLC whose disease progressed on treatment with TAGRISSO.</p>\n<p>The module enrolled an all-comer population of patients with <i>EGFR</i>m<i> </i>NSCLC and evaluated two doses of datopotamab deruxtecan-dlnk (4 or 6 mg/kg) which, in combination with TAGRISSO<i>, </i>showed similar ORRs of 43% (80% CI 31-55%) and 36% (80% CI 25-49%), respectively. PFS and DoR results favored the 6 mg/kg dose with a mPFS of 11.7 months (95% CI 8.3, NC) and 64% of patients continuing to respond at 9 months versus a mPFS of 9.5 months (95% CI 7.2-9.8) and 15% of patients continuing to respond at 9 months on the 4 mg/kg dose.</p>\n<p>The safety profile of TAGRISSO plus datopotamab deruxtecan-dlnk was consistent with the known safety profiles of each medicine and no new safety concerns were identified at either dose level. Grade 3 or higher treatment-related AEs occurred in 34% and 56% of patients receiving the 4 mg/kg or 6 mg/kg doses, respectively.</p>\n<p>Datopotamab deruxtecan-dlnk is a specifically engineered TROP2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The Companies are evaluating datopotamab deruxtecan-dlnk alone and with TAGRISSO as treatment for patients with advanced or metastatic <i>EGFR</i>m NSCLC in the TROPION-Lung14 and TROPION-Lung15 Phase III trials.</p>\n<p><b>New results for TAGRISSO plus chemotherapy in the 1st-line setting reinforce strong PFS benefit in FLAURA2 Phase III trial<br/></b>An exploratory post-hoc analysis of the FLAURA2 Phase III trial assessed PFS by length of exposure to pemetrexed maintenance treatment in patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) <i>EGFR</i>m NSCLC. Patients were treated with TAGRISSO with the addition of chemotherapy (pemetrexed plus cisplatin) followed by maintenance treatment with TAGRISSO<i> </i>and chemotherapy (pemetrexed) or TAGRISSO alone. Results showed an mPFS of more than two years regardless of length of pemetrexed maintenance exposure, with a trend associating longer PFS with longer pemetrexed treatment.</p>\n<p>The safety profile of TAGRISSO plus chemotherapy was consistent with the established profiles of the individual medicines. Grade 3 or higher chemotherapy-related AEs were reported in 16% of patients who received maintenance treatment for 3 to less than 9 months, and 10% for patients who received maintenance for 9 or more months. Chemotherapy discontinuation rates due to AEs were 18% and 10%, respectively.</p>\n<p>TAGRISSO plus chemotherapy previously demonstrated a statistically significant and clinically meaningful improvement in PFS. These results were published in <i>The New England Journal of Medicine</i> and formed the basis for regulatory approvals around the world including in the US, EU, Japan and China. Previously presented OS data from the second interim analysis showed a favorable trend with the TAGRISSO plus chemotherapy arm (HR 0.75; 95% CI 0.57-0.97, maturity 41%), with consistent results across all prespecified subgroups. The trial will continue to assess OS as a key secondary endpoint.</p>\n<p><b>IMPORTANT SAFETY INFORMATION</b></p>\n<ul>\n<li>There are no contraindications for TAGRISSO</li>\n<li>TAGRISSO can cause severe and fatal interstitial lung disease (ILD)/pneumonitis. ILD/pneumonitis occurred in 4% of the 1813 patients treated with TAGRISSO monotherapy who had not received recent definitive chemoradiation therapy; 0.4% of cases were fatal<br/><b>ILD/Pneumonitis with TAGRISSO in combination with Pemetrexed and Platinum-based Chemotherapy:</b><br/></li>\n</ul>\n<ul>\n<li>In the FLAURA2 study, ILD/pneumonitis occurred in 3.3% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 0.4% of cases were fatal</li>\n</ul>\n<p><b>ILD/Pneumonitis Following Definitive Platinum-based Chemoradiation Therapy (CRT):</b></p>\n<ul>\n<li>In the LAURA study, following definitive platinum-based CRT, ILD/pneumonitis including radiation pneumonitis, occurred in 80 of the 143 patients (56%) who received TAGRISSO monotherapy and 28 of the 73 patients (38%) who received placebo. There was one fatal case (0.7%), 3.5% Grade 3, 34% Grade 2, and 18% Grade 1 adverse reactions of ILD/pneumonitis in TAGRISSO-treated patients. For TAGRISSO-treated patients, ILD/pneumonitis led to permanent discontinuation of TAGRISSO in 7% of patients and dosage interruptions of TAGRISSO in 35% of patients. Among the 46 patients who were rechallenged with TAGRISSO, 11% had recurrence of ILD/pneumonitis. In the 80 TAGRISSO-treated patients, ILD/pneumonitis resolved in 40%, resolved with sequelae in 1.3%, were resolving in 16%, did not resolve in 41%, and resulted in death in 1.3%</li>\n</ul>\n<p>For patients receiving TAGRISSO who have not received recent definitive platinum-based CRT, withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed. For patients who have received recent definitive platinum-based CRT with Grade 1 ILD/pneumonitis, continue TAGRISSO or interrupt and restart, as appropriate. Permanently discontinue TAGRISSO in patients diagnosed with Grade ≥2 ILD/pneumonitis</p>\n<ul>\n<li>TAGRISSO can cause heart rate-corrected QT (QTc) interval prolongation. Of the 1813 TAGRISSO monotherapy-treated patients in clinical trials, 1.1% were found to have a QTc &gt;500 msec, and 4.3% of patients had an increase from baseline QTc &gt;60 msec. Of the 276 patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy in the FLAURA2 study, 1.8% were found to have a QTc &gt;500 msec, and 10.5% of patients had an increase from baseline QTc &gt;60 msec. No QTc-related arrhythmias were reported. Clinical trials of TAGRISSO did not enroll patients with baseline QTc of &gt;470 msec. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia</li>\n</ul>\n<ul>\n<li>TAGRISSO can cause cardiomyopathy, including cardiac failure, chronic cardiac failure, congestive heart failure, pulmonary edema or decreased ejection fraction. Cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. In the FLAURA2 study, cardiomyopathy occurred in 9% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 1.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to &lt;50% LVEF occurred in 4.2% of 1557 patients who had baseline and at least one follow-up LVEF assessment. In the ADAURA study, 1.5% (5/325) of TAGRISSO-treated patients experienced LVEF decreases ≥10% from baseline and a drop to &lt;50%. In the LAURA study, following platinum-based CRT, 3% (4/135) of TAGRISSO-treated patients and no placebo-treated patients experienced LVEF decreases ≥10% and a drop to &lt;50%. In the FLAURA2 study, 8% (21/262) of patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, who had baseline and at least one follow-up LVEF assessment, experienced LVEF decreases ≥10% and a drop to &lt;50%. For patients receiving TAGRISSO monotherapy, conduct cardiac monitoring in patients with cardiac risk factors, including assessment of LVEF at baseline and during treatment. For patients receiving TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, conduct cardiac monitoring in all patients, including assessment of LVEF at baseline and during treatment. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO</li>\n</ul>\n<ul>\n<li>Keratitis was reported in 0.6% of 1813 patients treated with TAGRISSO monotherapy in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist</li>\n</ul>\n<ul>\n<li>Postmarketing cases consistent with erythema multiforme major (EMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if EMM, SJS, or TEN is suspected and permanently discontinue if confirmed</li>\n</ul>\n<ul>\n<li>Postmarketing cases of cutaneous vasculitis including leukocytoclastic vasculitis, urticarial vasculitis, and IgA vasculitis have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if cutaneous vasculitis is suspected, evaluate for systemic involvement, and consider dermatology consultation. If no other etiology can be identified, consider permanent discontinuation of TAGRISSO based on severity</li>\n</ul>\n<ul>\n<li>Aplastic anemia has been reported in TAGRISSO-treated patients in clinical trials (0.06% of 1813) and postmarketing. Some cases had a fatal outcome. Inform patients of the signs and symptoms of aplastic anemia including but not limited to, new or persistent fevers, bruising, bleeding, and pallor. If aplastic anemia is suspected, withhold TAGRISSO and obtain a hematology consultation. If aplastic anemia is confirmed, permanently discontinue TAGRISSO. Perform complete blood count with differential before starting TAGRISSO, periodically throughout treatment, and more frequently if indicated</li>\n</ul>\n<ul>\n<li>Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the last dose</li>\n</ul>\n<ul>\n<li>Because of the potential for serious adverse reactions in breastfed infants from TAGRISSO, women should not breastfeed during treatment with TAGRISSO and for 2 weeks after the last dose</li>\n</ul>\n<ul>\n<li>Most common (≥20%) adverse reactions, including laboratory abnormalities, were:\n  <ul>\n<li>TAGRISSO monotherapy: leukopenia, lymphopenia, thrombocytopenia, anemia, diarrhea, rash, musculoskeletal pain, neutropenia, nail toxicity, dry skin, stomatitis, and fatigue</li>\n<li>TAGRISSO monotherapy following platinum-based chemoradiation therapy<b>: </b>lymphopenia, leukopenia, ILD/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal pain, cough and COVID-19</li>\n<li>TAGRISSO in combination with pemetrexed and platinum-based chemotherapy: leukopenia, thrombocytopenia, neutropenia, lymphopenia, rash, diarrhea, stomatitis, nail toxicity, dry skin, and increased blood creatinine</li>\n</ul></li>\n</ul>\n<p><b>INDICATIONS</b></p>\n<ul>\n<li>TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test</li>\n<li>TAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test</li>\n<li>TAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test</li>\n<li>TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test</li>\n<li>TAGRISSO is indicated for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy</li>\n</ul>\n<p><b>Notes<br/></b><b>NSCLC<br/></b>Lung cancer is the leading cause of cancer death among men and women, accounting for about one-fifth of all cancer deaths.<sup>1</sup> Lung cancer is broadly split into small cell lung cancer or NSCLC, the latter accounting for about 80% of cases.<sup>2</sup> Approximately 10 to 15% of patients with NSCLC in the US and Europe and 30 to 40% of patients in Asia have an <i>EGFR </i>mutation.<sup>3-5</sup></p>\n<p>While <i>EGFR-</i>TKIs have significantly improved outcomes in the 1st-line setting, mechanisms of resistance and disease progression are extremely common, and a significant unmet need exists in later-line settings for effective and well-tolerated treatment options.<sup>6-9</sup></p>\n<p><b>LAURA<br/></b>LAURA is a randomized, double-blind, placebo-controlled, multi-center, global Phase III trial in patients with unresectable, Stage III <i>EGFR</i>m NSCLC whose disease has not progressed following definitive platinum-based CRT. Patients were treated with TAGRISSO 80 mg once-daily (QD) oral tablets until disease progression, unacceptable toxicity or other discontinuation criteria were met. Upon progression, patients in the placebo arm were offered treatment with TAGRISSO.</p>\n<p>The trial enrolled 216 patients in more than 145 centers across more than 15 countries, including in the US, Europe, South America and Asia.</p>\n<p><b>SAVANNAH<br/></b>SAVANNAH is an ongoing randomized, global Phase II trial studying the efficacy of savolitinib added to TAGRISSO in patients with <i>EGFR</i>m, locally advanced or metastatic NSCLC with <i>MET</i> overexpression and/or amplification whose disease progressed following treatment with TAGRISSO. Based on the original single-arm trial design, patients were treated with savolitinib 300 or 600 mg QD or 300 mg BID, in combination with oral TAGRISSO 80 mg QD. In 2022, a comparison of savolitinib 300 mg BID and TAGRISSO 80 mg QD to savolitinib 300 mg BID and placebo was added to the trial to evaluate contribution of components.</p>\n<p>The trial has enrolled 369 patients to date in more than 80 centers globally, including in the US, Canada, Europe, South America and Asia. The primary endpoint is ORR and key secondary endpoints include PFS and DoR.</p>\n<p>In August 2022, positive interim ORR results from the SAVANNAH trial were presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).</p>\n<p>The global SAFFRON Phase III trial will further assess the TAGRISSO<i> </i>plus savolitinib combination versus platinum-based doublet chemotherapy in patients with <i>EGFR</i>m, <i>MET</i>-overexpressed and/or amplified, locally advanced or metastatic NSCLC following treatment with TAGRISSO. Patients are being prospectively selected using the high <i>MET</i> level cut-off identified in SAVANNAH.</p>\n<p><b>ORCHARD<br/></b>ORCHARD (<span>O</span>simertinib <span>R</span>esistance <span>C</span>o<span>H</span>orts, <span>A</span>ddressing 1L <span>R</span>elapse <span>D</span>rivers) is an open-label, multi-center Phase II platform trial evaluating numerous TAGRISSO-based combinations as a treatment for patients with advanced <i>EGFR</i>m NSCLC whose disease has progressed on 1st-line TAGRISSO. The trial has 10 modules examining the efficacy, safety and tolerability of these targeted and non-targeted combination options, including TAGRISSO<i> </i>80 mg QD plus datopotamab deruxtecan-dlnk given intravenously at 4 or 6 mg/kg on day one of every three-week cycle.</p>\n<p>The trial has enrolled 247 patients to date in more than 40 centers globally, including in the US, Europe and Asia. The primary endpoint is ORR. Key secondary endpoints include PFS and DoR.</p>\n<p><b>FLAURA2<br/></b>FLAURA2 is a randomized, open-label, multi-center, global Phase III trial in the 1st-line treatment of patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) <i>EGFR</i>m NSCLC. Patients were treated with TAGRISSO<i> </i>80 mg QD oral tablets with the addition of chemotherapy (pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) every three weeks for four cycles, followed by TAGRISSO<i> </i>with pemetrexed maintenance every three weeks.</p>\n<p>The trial enrolled 557 patients in more than 150 centers across more than 20 countries, including in the US, Europe, South America and Asia. The primary endpoint is PFS. The trial is ongoing and will continue to assess the secondary endpoint of OS.</p>\n<p><b>TAGRISSO<br/></b>TAGRISSO<sup>®</sup><i> </i>(osimertinib) is a third-generation, irreversible <i>EGFR</i>-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. TAGRISSO (40 mg and 80 mg QD oral tablets) has been used to treat patients across its indications worldwide and AstraZeneca continues to explore TAGRISSO as a treatment for patients across multiple stages of <i>EGFR</i>m NSCLC.</p>\n<p>There is an extensive body of evidence supporting the use of TAGRISSO in <i>EGFR</i>m NSCLC. TAGRISSO is the only targeted therapy to improve patient outcomes in early-stage disease in the NeoADAURA and ADAURA Phase III trials, locally advanced stages in the LAURA Phase III trial and late-stage disease in the FLAURA and FLAURA2 Phase III trials.</p>\n<p>As part of AstraZeneca’s ongoing commitment to treating patients as early as possible in lung cancer, TAGRISSO is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.</p>\n<p><b>Savolitinib<br/></b>Savolitinib is an oral, potent, and highly selective <i>MET</i> TKI that has demonstrated clinical activity in advanced solid tumors. <i>MET</i> is a tyrosine kinase receptor that has an essential role in normal cell development. Savolitinib blocks atypical activation of the <i>MET</i> receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. <i>MET</i> overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is a known mechanism of acquired resistance to <i>EGFR</i> TKIs. The prevalence of <i>MET</i> depends on the sample type, detection method and assay cut-off used.</p>\n<p>Savolitinib is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with <i>MET</i> exon 14 skipping alterations.</p>\n<p>It is currently under clinical development for multiple tumor types, including lung, kidney and gastric cancers as a single treatment and in combination with other medicines.</p>\n<p><b>Datopotamab deruxtecan-dlnk<br/></b>Datopotamab deruxtecan-dlnk (datopotamab deruxtecan in rest of world) is a TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan-dlnk is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan-dlnk is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.</p>\n<p>Datopotamab deruxtecan-dlnk (6 mg/kg) is approved in the US, Japan and Russia for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease based on the results from the TROPION-Breast01 Phase III trial.</p>\n<p>In the US, a Biologics License Application for datopotamab deruxtecan-dlnk is under Priority Review for the treatment of adult patients with locally advanced or metastatic <i>EGFR</i>m NSCLC who have received prior systemic therapies, including an <i>EGFR</i>-directed therapy. Datopotamab deruxtecan-dlnk was also granted Breakthrough Therapy Designation by the FDA for this patient population.</p>\n<p><b>AstraZeneca in lung cancer<br/></b>AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most.</p>\n<p>The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including TAGRISSO and gefitinib; durvalumab and tremelimumab-actl; fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan-dlnk in collaboration with Daiichi Sankyo; savolitinib in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.</p>\n<p>AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.</p>\n<p><b>AstraZeneca in oncology<br/></b>AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.</p>\n<p>The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.</p>\n<p>AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.</p>\n<p><b>AstraZeneca<br/></b>AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp; Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.</p>\n<p><b>References</b></p>\n<ol>\n<li>World Health Organization. International agency for research on cancer: lung cancer fact sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed March 2025.</li>\n<li>American Cancer Society. What is lung cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed March 2025.</li>\n<li>Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. <i>J Clin Oncol</i>. 2011;29:2121-2127.</li>\n<li>Szumera-Ciećkiewicz A, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a polish, single institution study and systematic review of european incidence. <i>Int J Clin Exp Pathol</i>. 2013;6:2800-2812.</li>\n<li>Ellison G, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. <i>J Clin Pathol</i>. 2013;66:79-89.</li>\n<li>Chen R, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. <i>J Hematol Oncol</i>. 2020;13(1):58.</li>\n<li>Majeed U, et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. <i>J Hematol Oncol</i>. 2021;14(1):108.</li>\n<li>Morgillo F, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. <i>ESMO Open</i>. 2016;1(3):e000060.</li>\n<li>Han B, et al. Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. <i>Onco Targets Ther</i>. 2018;11:2121-2129.</li>\n</ol>\n<p>US-99612 Last Updated 3/25</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250325308922/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Media Inquiries </b><br/>Fiona Cookson, +1 212 814 3923<br/>Chelsea Tressler, +1 302 885 2677<br/><br/>US Media Mailbox: usmediateam@astrazeneca.com<br/><br/><br/><br/></p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-26 07:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/study-results-reinforce-tagrisso-osimertinib-230200995.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting\nSAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or ...</p>\n\n<a href=\"https://finance.yahoo.com/news/study-results-reinforce-tagrisso-osimertinib-230200995.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4195":"互助储蓄与抵押信贷金融服务","BK4166":"消费信贷","TEN":"Tsakos Energy Navigation Ltd","BK4588":"碎股","BK4568":"美国抗疫概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4503":"景林资产持仓","BK4231":"零售房地产信托","BK4097":"系统软件","ADC":"艾格里房产","BK4080":"零售业房地产投资信托","BK4124":"机动车零配件与设备","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4563":"昨日强势股","ORR":"Militia Long/Short Equity ETF","OS":"Onestream Inc","AZN":"阿斯利康","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4213":"石油与天然气的勘探与生产","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","PFS":"Provident Financial Services Inc","BK4144":"石油与天然气的储存和运输","CRT":"CRT信托","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","EMM":"GLOBAL X EMERGING MARKETS ETF","BK4007":"制药","BK4211":"区域性银行","QD":"趣店"},"source_url":"https://finance.yahoo.com/news/study-results-reinforce-tagrisso-osimertinib-230200995.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2522837332","content_text":"In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting\nSAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity\nWILMINGTON, Del., March 25, 2025--(BUSINESS WIRE)--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include:\n\nLAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy (CRT) (LBA4).\nSAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with high levels of MET overexpression and/or amplification following disease progression on 1st-line TAGRISSO (#2O).\nORCHARD Phase II platform trial of TAGRISSO plus datopotamab deruxtecan-dlnk in advanced EGFRm NSCLC following disease progression on 1st-line TAGRISSO (#1O).\nFLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced EGFRm NSCLC (#53P).\n\nMyung-Ju Ahn, MD, PhD, Professor of Hemato-Oncology at the Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, said: \"A critical goal in treating every patient with lung cancer is to not only extend a patient's life but also maintain quality of life while on treatment. The continued overall survival trend seen here at ELCC in the unresectable Stage III setting and the promising data for combinations that can address progression in the advanced setting, together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment.\"\nSusan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca, said: \"Having now treated more than one million patients around the world, TAGRISSO has repeatedly transformed expectations for patients with EGFR-mutated lung cancer by not only extending survival but also showing it is possible to maintain quality of life during cancer treatment. The breadth of data at ELCC reinforce TAGRISSO as the backbone therapy for patients with this disease and show that adding savolitinib or datopotamab deruxtecan-dlnk at the time of disease progression can help prolong patients’ responses to treatment.\"\nProfessor Virginia Harrison, EGFR Positive UK, said: \"For people undergoing treatment for lung cancer, maintaining quality of life is so important, but it can be challenging. The development of simple and effective treatment regimens that minimize negative side effects can make a huge difference. We are excited to see this progress for patients with EGFR-mutated lung cancer, where there is still significant unmet need.\"\nTAGRISSO continued to demonstrate encouraging overall survival (OS) trend in unresectable, Stage III setting in LAURA trialUpdated results from the LAURA Phase III trial showed an improved trend towards OS benefit with TAGRISSO compared to placebo in patients with unresectable, Stage III EGFRm NSCLC (hazard ratio [HR] 0.67; 95% confidence interval [CI] 0.40, 1.14, maturity 31%). Median OS was 58.8 months (95% CI 54.1, not calculable [NC]) in patients treated with TAGRISSO versus 54.1 months with placebo (95% CI 42.1, NC), despite 78% of patients on placebo receiving subsequent treatment with TAGRISSO upon progression. The trial will continue to assess OS as a key secondary endpoint at the final analysis.\nTAGRISSO previously demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS). These results were published in The New England Journal of Medicine and formed the basis for regulatory approvals around the world including in the US, EU and China.\nSafety results and discontinuation rates due to adverse events (AEs) were as expected and no new safety concerns were identified.\nTAGRISSO plus savolitinib showed durable response rates in lung cancer patients with high levels of MET overexpression and/or amplification whose disease progressed on 1st-line TAGRISSO in SAVANNAH trialResults from the SAVANNAH Phase II trial showed TAGRISSO plus savolitinib (300 mg twice-daily [BID]) demonstrated a clinically meaningful and durable objective response rate (ORR) in patients with EGFRm NSCLC with high levels of MET overexpression and/or amplification whose disease progressed on treatment with 1st-line TAGRISSO. Among patients screened for enrollment in SAVANNAH, an estimated 62% had tumors with MET overexpression and/or amplification, and approximately 34% met the defined high MET level cut-off.\nTAGRISSO plus savolitinib demonstrated a confirmed ORR of 56% (95% CI 45-67%), with a median duration of response (DoR) of 7.1 months (95% CI 5.6-9.6). Median PFS (mPFS) was 7.4 months (95% CI 5.5-7.6).\nSafety results and discontinuation rates due to AEs were consistent with the established profiles of each medicine and no new safety concerns were reported. In all patients treated with TAGRISSO plus savolitinib (300 mg BID), Grade 3 or higher AEs occurred in 57% of patients.\nSavolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (TKI) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, TAGRISSO plus savolitinib received Fast Track designation from the Food and Drug Administration (FDA) in this setting.\nTAGRISSO plus datopotamab deruxtecan-dlnk showed encouraging response rates in patients whose disease progressed on 1st-line TAGRISSO in ORCHARD trialFirst results from the TAGRISSO plus datopotamab deruxtecan-dlnk module of the ORCHARD Phase II platform trial showed the combination demonstrated promising efficacy and manageable safety in patients with advanced EGFRm NSCLC whose disease progressed on treatment with TAGRISSO.\nThe module enrolled an all-comer population of patients with EGFRm NSCLC and evaluated two doses of datopotamab deruxtecan-dlnk (4 or 6 mg/kg) which, in combination with TAGRISSO, showed similar ORRs of 43% (80% CI 31-55%) and 36% (80% CI 25-49%), respectively. PFS and DoR results favored the 6 mg/kg dose with a mPFS of 11.7 months (95% CI 8.3, NC) and 64% of patients continuing to respond at 9 months versus a mPFS of 9.5 months (95% CI 7.2-9.8) and 15% of patients continuing to respond at 9 months on the 4 mg/kg dose.\nThe safety profile of TAGRISSO plus datopotamab deruxtecan-dlnk was consistent with the known safety profiles of each medicine and no new safety concerns were identified at either dose level. Grade 3 or higher treatment-related AEs occurred in 34% and 56% of patients receiving the 4 mg/kg or 6 mg/kg doses, respectively.\nDatopotamab deruxtecan-dlnk is a specifically engineered TROP2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The Companies are evaluating datopotamab deruxtecan-dlnk alone and with TAGRISSO as treatment for patients with advanced or metastatic EGFRm NSCLC in the TROPION-Lung14 and TROPION-Lung15 Phase III trials.\nNew results for TAGRISSO plus chemotherapy in the 1st-line setting reinforce strong PFS benefit in FLAURA2 Phase III trialAn exploratory post-hoc analysis of the FLAURA2 Phase III trial assessed PFS by length of exposure to pemetrexed maintenance treatment in patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC. Patients were treated with TAGRISSO with the addition of chemotherapy (pemetrexed plus cisplatin) followed by maintenance treatment with TAGRISSO and chemotherapy (pemetrexed) or TAGRISSO alone. Results showed an mPFS of more than two years regardless of length of pemetrexed maintenance exposure, with a trend associating longer PFS with longer pemetrexed treatment.\nThe safety profile of TAGRISSO plus chemotherapy was consistent with the established profiles of the individual medicines. Grade 3 or higher chemotherapy-related AEs were reported in 16% of patients who received maintenance treatment for 3 to less than 9 months, and 10% for patients who received maintenance for 9 or more months. Chemotherapy discontinuation rates due to AEs were 18% and 10%, respectively.\nTAGRISSO plus chemotherapy previously demonstrated a statistically significant and clinically meaningful improvement in PFS. These results were published in The New England Journal of Medicine and formed the basis for regulatory approvals around the world including in the US, EU, Japan and China. Previously presented OS data from the second interim analysis showed a favorable trend with the TAGRISSO plus chemotherapy arm (HR 0.75; 95% CI 0.57-0.97, maturity 41%), with consistent results across all prespecified subgroups. The trial will continue to assess OS as a key secondary endpoint.\nIMPORTANT SAFETY INFORMATION\n\nThere are no contraindications for TAGRISSO\nTAGRISSO can cause severe and fatal interstitial lung disease (ILD)/pneumonitis. ILD/pneumonitis occurred in 4% of the 1813 patients treated with TAGRISSO monotherapy who had not received recent definitive chemoradiation therapy; 0.4% of cases were fatalILD/Pneumonitis with TAGRISSO in combination with Pemetrexed and Platinum-based Chemotherapy:\n\n\nIn the FLAURA2 study, ILD/pneumonitis occurred in 3.3% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 0.4% of cases were fatal\n\nILD/Pneumonitis Following Definitive Platinum-based Chemoradiation Therapy (CRT):\n\nIn the LAURA study, following definitive platinum-based CRT, ILD/pneumonitis including radiation pneumonitis, occurred in 80 of the 143 patients (56%) who received TAGRISSO monotherapy and 28 of the 73 patients (38%) who received placebo. There was one fatal case (0.7%), 3.5% Grade 3, 34% Grade 2, and 18% Grade 1 adverse reactions of ILD/pneumonitis in TAGRISSO-treated patients. For TAGRISSO-treated patients, ILD/pneumonitis led to permanent discontinuation of TAGRISSO in 7% of patients and dosage interruptions of TAGRISSO in 35% of patients. Among the 46 patients who were rechallenged with TAGRISSO, 11% had recurrence of ILD/pneumonitis. In the 80 TAGRISSO-treated patients, ILD/pneumonitis resolved in 40%, resolved with sequelae in 1.3%, were resolving in 16%, did not resolve in 41%, and resulted in death in 1.3%\n\nFor patients receiving TAGRISSO who have not received recent definitive platinum-based CRT, withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed. For patients who have received recent definitive platinum-based CRT with Grade 1 ILD/pneumonitis, continue TAGRISSO or interrupt and restart, as appropriate. Permanently discontinue TAGRISSO in patients diagnosed with Grade ≥2 ILD/pneumonitis\n\nTAGRISSO can cause heart rate-corrected QT (QTc) interval prolongation. Of the 1813 TAGRISSO monotherapy-treated patients in clinical trials, 1.1% were found to have a QTc >500 msec, and 4.3% of patients had an increase from baseline QTc >60 msec. Of the 276 patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy in the FLAURA2 study, 1.8% were found to have a QTc >500 msec, and 10.5% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Clinical trials of TAGRISSO did not enroll patients with baseline QTc of >470 msec. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia\n\n\nTAGRISSO can cause cardiomyopathy, including cardiac failure, chronic cardiac failure, congestive heart failure, pulmonary edema or decreased ejection fraction. Cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. In the FLAURA2 study, cardiomyopathy occurred in 9% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 1.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 4.2% of 1557 patients who had baseline and at least one follow-up LVEF assessment. In the ADAURA study, 1.5% (5/325) of TAGRISSO-treated patients experienced LVEF decreases ≥10% from baseline and a drop to <50%. In the LAURA study, following platinum-based CRT, 3% (4/135) of TAGRISSO-treated patients and no placebo-treated patients experienced LVEF decreases ≥10% and a drop to <50%. In the FLAURA2 study, 8% (21/262) of patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, who had baseline and at least one follow-up LVEF assessment, experienced LVEF decreases ≥10% and a drop to <50%. For patients receiving TAGRISSO monotherapy, conduct cardiac monitoring in patients with cardiac risk factors, including assessment of LVEF at baseline and during treatment. For patients receiving TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, conduct cardiac monitoring in all patients, including assessment of LVEF at baseline and during treatment. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO\n\n\nKeratitis was reported in 0.6% of 1813 patients treated with TAGRISSO monotherapy in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist\n\n\nPostmarketing cases consistent with erythema multiforme major (EMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if EMM, SJS, or TEN is suspected and permanently discontinue if confirmed\n\n\nPostmarketing cases of cutaneous vasculitis including leukocytoclastic vasculitis, urticarial vasculitis, and IgA vasculitis have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if cutaneous vasculitis is suspected, evaluate for systemic involvement, and consider dermatology consultation. If no other etiology can be identified, consider permanent discontinuation of TAGRISSO based on severity\n\n\nAplastic anemia has been reported in TAGRISSO-treated patients in clinical trials (0.06% of 1813) and postmarketing. Some cases had a fatal outcome. Inform patients of the signs and symptoms of aplastic anemia including but not limited to, new or persistent fevers, bruising, bleeding, and pallor. If aplastic anemia is suspected, withhold TAGRISSO and obtain a hematology consultation. If aplastic anemia is confirmed, permanently discontinue TAGRISSO. Perform complete blood count with differential before starting TAGRISSO, periodically throughout treatment, and more frequently if indicated\n\n\nVerify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the last dose\n\n\nBecause of the potential for serious adverse reactions in breastfed infants from TAGRISSO, women should not breastfeed during treatment with TAGRISSO and for 2 weeks after the last dose\n\n\nMost common (≥20%) adverse reactions, including laboratory abnormalities, were:\n  \nTAGRISSO monotherapy: leukopenia, lymphopenia, thrombocytopenia, anemia, diarrhea, rash, musculoskeletal pain, neutropenia, nail toxicity, dry skin, stomatitis, and fatigue\nTAGRISSO monotherapy following platinum-based chemoradiation therapy: lymphopenia, leukopenia, ILD/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal pain, cough and COVID-19\nTAGRISSO in combination with pemetrexed and platinum-based chemotherapy: leukopenia, thrombocytopenia, neutropenia, lymphopenia, rash, diarrhea, stomatitis, nail toxicity, dry skin, and increased blood creatinine\n\n\nINDICATIONS\n\nTAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test\nTAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test\nTAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test\nTAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test\nTAGRISSO is indicated for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy\n\nNotesNSCLCLung cancer is the leading cause of cancer death among men and women, accounting for about one-fifth of all cancer deaths.1 Lung cancer is broadly split into small cell lung cancer or NSCLC, the latter accounting for about 80% of cases.2 Approximately 10 to 15% of patients with NSCLC in the US and Europe and 30 to 40% of patients in Asia have an EGFR mutation.3-5\nWhile EGFR-TKIs have significantly improved outcomes in the 1st-line setting, mechanisms of resistance and disease progression are extremely common, and a significant unmet need exists in later-line settings for effective and well-tolerated treatment options.6-9\nLAURALAURA is a randomized, double-blind, placebo-controlled, multi-center, global Phase III trial in patients with unresectable, Stage III EGFRm NSCLC whose disease has not progressed following definitive platinum-based CRT. Patients were treated with TAGRISSO 80 mg once-daily (QD) oral tablets until disease progression, unacceptable toxicity or other discontinuation criteria were met. Upon progression, patients in the placebo arm were offered treatment with TAGRISSO.\nThe trial enrolled 216 patients in more than 145 centers across more than 15 countries, including in the US, Europe, South America and Asia.\nSAVANNAHSAVANNAH is an ongoing randomized, global Phase II trial studying the efficacy of savolitinib added to TAGRISSO in patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression and/or amplification whose disease progressed following treatment with TAGRISSO. Based on the original single-arm trial design, patients were treated with savolitinib 300 or 600 mg QD or 300 mg BID, in combination with oral TAGRISSO 80 mg QD. In 2022, a comparison of savolitinib 300 mg BID and TAGRISSO 80 mg QD to savolitinib 300 mg BID and placebo was added to the trial to evaluate contribution of components.\nThe trial has enrolled 369 patients to date in more than 80 centers globally, including in the US, Canada, Europe, South America and Asia. The primary endpoint is ORR and key secondary endpoints include PFS and DoR.\nIn August 2022, positive interim ORR results from the SAVANNAH trial were presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).\nThe global SAFFRON Phase III trial will further assess the TAGRISSO plus savolitinib combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following treatment with TAGRISSO. Patients are being prospectively selected using the high MET level cut-off identified in SAVANNAH.\nORCHARDORCHARD (Osimertinib Resistance CoHorts, Addressing 1L Relapse Drivers) is an open-label, multi-center Phase II platform trial evaluating numerous TAGRISSO-based combinations as a treatment for patients with advanced EGFRm NSCLC whose disease has progressed on 1st-line TAGRISSO. The trial has 10 modules examining the efficacy, safety and tolerability of these targeted and non-targeted combination options, including TAGRISSO 80 mg QD plus datopotamab deruxtecan-dlnk given intravenously at 4 or 6 mg/kg on day one of every three-week cycle.\nThe trial has enrolled 247 patients to date in more than 40 centers globally, including in the US, Europe and Asia. The primary endpoint is ORR. Key secondary endpoints include PFS and DoR.\nFLAURA2FLAURA2 is a randomized, open-label, multi-center, global Phase III trial in the 1st-line treatment of patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC. Patients were treated with TAGRISSO 80 mg QD oral tablets with the addition of chemotherapy (pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) every three weeks for four cycles, followed by TAGRISSO with pemetrexed maintenance every three weeks.\nThe trial enrolled 557 patients in more than 150 centers across more than 20 countries, including in the US, Europe, South America and Asia. The primary endpoint is PFS. The trial is ongoing and will continue to assess the secondary endpoint of OS.\nTAGRISSOTAGRISSO® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. TAGRISSO (40 mg and 80 mg QD oral tablets) has been used to treat patients across its indications worldwide and AstraZeneca continues to explore TAGRISSO as a treatment for patients across multiple stages of EGFRm NSCLC.\nThere is an extensive body of evidence supporting the use of TAGRISSO in EGFRm NSCLC. TAGRISSO is the only targeted therapy to improve patient outcomes in early-stage disease in the NeoADAURA and ADAURA Phase III trials, locally advanced stages in the LAURA Phase III trial and late-stage disease in the FLAURA and FLAURA2 Phase III trials.\nAs part of AstraZeneca’s ongoing commitment to treating patients as early as possible in lung cancer, TAGRISSO is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.\nSavolitinibSavolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. MET is a tyrosine kinase receptor that has an essential role in normal cell development. Savolitinib blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. MET overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is a known mechanism of acquired resistance to EGFR TKIs. The prevalence of MET depends on the sample type, detection method and assay cut-off used.\nSavolitinib is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alterations.\nIt is currently under clinical development for multiple tumor types, including lung, kidney and gastric cancers as a single treatment and in combination with other medicines.\nDatopotamab deruxtecan-dlnkDatopotamab deruxtecan-dlnk (datopotamab deruxtecan in rest of world) is a TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan-dlnk is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan-dlnk is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.\nDatopotamab deruxtecan-dlnk (6 mg/kg) is approved in the US, Japan and Russia for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease based on the results from the TROPION-Breast01 Phase III trial.\nIn the US, a Biologics License Application for datopotamab deruxtecan-dlnk is under Priority Review for the treatment of adult patients with locally advanced or metastatic EGFRm NSCLC who have received prior systemic therapies, including an EGFR-directed therapy. Datopotamab deruxtecan-dlnk was also granted Breakthrough Therapy Designation by the FDA for this patient population.\nAstraZeneca in lung cancerAstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most.\nThe Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including TAGRISSO and gefitinib; durvalumab and tremelimumab-actl; fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan-dlnk in collaboration with Daiichi Sankyo; savolitinib in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.\nAstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.\nAstraZeneca in oncologyAstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.\nThe Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.\nAstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.\nAstraZenecaAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.\nReferences\n\nWorld Health Organization. International agency for research on cancer: lung cancer fact sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed March 2025.\nAmerican Cancer Society. What is lung cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed March 2025.\nKeedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121-2127.\nSzumera-Ciećkiewicz A, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a polish, single institution study and systematic review of european incidence. Int J Clin Exp Pathol. 2013;6:2800-2812.\nEllison G, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66:79-89.\nChen R, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58.\nMajeed U, et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108.\nMorgillo F, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1(3):e000060.\nHan B, et al. Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. Onco Targets Ther. 2018;11:2121-2129.\n\nUS-99612 Last Updated 3/25\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250325308922/en/\nContacts\nMedia Inquiries Fiona Cookson, +1 212 814 3923Chelsea Tressler, +1 302 885 2677US Media Mailbox: usmediateam@astrazeneca.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":20,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421312732614784,"gmtCreate":1743844386644,"gmtModify":1743844388537,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MAGS\">$Roundhill Magnificent Seven ETF(MAGS)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/MAGS\">$Roundhill Magnificent Seven ETF(MAGS)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp;","text":"$Roundhill Magnificent Seven ETF(MAGS)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421312732614784","isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421300376944928,"gmtCreate":1743844359808,"gmtModify":1743845390423,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"US Market 24H and Overnight Trading - Help - Tiger Brokers","htmlText":"Find out more here:<a href=\"https://tigr.link/s/80Ap3NH\">US Market 24H and Overnight Trading - Help - Tiger Brokers</a>","listText":"Find out more here:<a href=\"https://tigr.link/s/80Ap3NH\">US Market 24H and Overnight Trading - Help - Tiger Brokers</a>","text":"Find out more here:US Market 24H and Overnight Trading - Help - Tiger Brokers","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421300376944928","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":418996400648400,"gmtCreate":1743287377947,"gmtModify":1743287381380,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Good<a href=\"https://ttm.financial/S/IOZ.AU\">$iShares Core S&amp;P/ASX 200(IOZ.AU)$ </a>&nbsp;","listText":"Good<a href=\"https://ttm.financial/S/IOZ.AU\">$iShares Core S&amp;P/ASX 200(IOZ.AU)$ </a>&nbsp;","text":"Good$iShares Core S&P/ASX 200(IOZ.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":22,"commentSize":2,"repostSize":8,"link":"https://ttm.financial/post/418996400648400","isVote":1,"tweetType":1,"viewCount":1181,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4091884160412060","authorId":"4091884160412060","name":"Aqa","avatar":"https://community-static.tradeup.com/news/4a899a6e247bc68815d3a2da3b82a81a","crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"4091884160412060","idStr":"4091884160412060"},"content":"Liked and shared","text":"Liked and shared","html":"Liked and shared"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420206322286888,"gmtCreate":1743620517429,"gmtModify":1743630108029,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"Cathie Wood’s ARK sells UiPath, buys more GitLab and Robinhood stock By Investing.com","htmlText":"Find out more here:<a href=\"https://ph.investing.com/news/company-news/cathie-woods-ark-sells-uipath-buys-more-gitlab-and-robinhood-stock-93CH-1748776?shareID=06c0fa69e06e2251f6776db84f411675&amp;invite=F4JURJ&amp;lang=en_AU&amp;platform=android&amp;utm_medium=tiger_community#google_vignette\">Cathie Wood’s ARK sells UiPath, buys more GitLab and Robinhood stock By Investing.com</a>","listText":"Find out more here:<a href=\"https://ph.investing.com/news/company-news/cathie-woods-ark-sells-uipath-buys-more-gitlab-and-robinhood-stock-93CH-1748776?shareID=06c0fa69e06e2251f6776db84f411675&amp;invite=F4JURJ&amp;lang=en_AU&amp;platform=android&amp;utm_medium=tiger_community#google_vignette\">Cathie Wood’s ARK sells UiPath, buys more GitLab and Robinhood stock By Investing.com</a>","text":"Find out more here:Cathie Wood’s ARK sells UiPath, buys more GitLab and Robinhood stock By Investing.com","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/420206322286888","isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421233960759576,"gmtCreate":1743845341502,"gmtModify":1743845346990,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"NZ STOCK MARKET QUOTES","htmlText":"Find out more here:<a href=\"https://tigr.link/s/50Ap8Nz\">NZ STOCK MARKET QUOTES</a> null","listText":"Find out more here:<a href=\"https://tigr.link/s/50Ap8Nz\">NZ STOCK MARKET QUOTES</a> null","text":"Find out more here:NZ STOCK MARKET QUOTES null","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421233960759576","isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420944488628416,"gmtCreate":1743800571172,"gmtModify":1743800573865,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"[Anger]&nbsp;&nbsp;[Speechless]&nbsp;&nbsp;[Speechless]&nbsp;&nbsp;[Speechless]&nbsp;&nbsp;<a href=\"https://ttm.financial/OPT/TSM 20250404 155.0 CALL\">$TSM 20250404 155.0 CALL$ </a>&nbsp;","listText":"[Anger]&nbsp;&nbsp;[Speechless]&nbsp;&nbsp;[Speechless]&nbsp;&nbsp;[Speechless]&nbsp;&nbsp;<a href=\"https://ttm.financial/OPT/TSM 20250404 155.0 CALL\">$TSM 20250404 155.0 CALL$ </a>&nbsp;","text":"[Anger] [Speechless] [Speechless] [Speechless] $TSM 20250404 155.0 CALL$","images":[{"img":"https://community-static.tradeup.com/news/e9cf02604794ba4229195a2d3dccd0f2","width":"937","height":"4481"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420944488628416","isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":420286833664352,"gmtCreate":1743639738891,"gmtModify":1743642206379,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"Help Center - Tiger Brokers","htmlText":"Find out more here:<a href=\"https://tigr.link/s/80AnfcS\">Help Center - Tiger Brokers</a> Tiger Brokers is a company listed on NASDAQ. With U.S. licenses, it has become the platform of choice for global Chinese investors to trade in the U.S. and Hong Kong. Investors can easily open accounts online with Tiger Brokers.","listText":"Find out more here:<a href=\"https://tigr.link/s/80AnfcS\">Help Center - Tiger Brokers</a> Tiger Brokers is a company listed on NASDAQ. With U.S. licenses, it has become the platform of choice for global Chinese investors to trade in the U.S. and Hong Kong. Investors can easily open accounts online with Tiger Brokers.","text":"Find out more here:Help Center - Tiger Brokers Tiger Brokers is a company listed on NASDAQ. With U.S. licenses, it has become the platform of choice for global Chinese investors to trade in the U.S. and Hong Kong. Investors can easily open accounts online with Tiger Brokers.","images":[{"img":"https://static.tigerbbs.com/ff98eccfaff055c5a7c86bee57069e0c"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/420286833664352","isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":418957609852992,"gmtCreate":1743278676893,"gmtModify":1743278680788,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/418957609852992","repostId":"418580862959912","repostType":1,"repost":{"id":418580862959912,"gmtCreate":1743188495799,"gmtModify":1743203402069,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIA\">$SPDR Dow Jones Industrial Average ETF Trust(DIA)$</a> b̰̃ḛ̃ã̰r̰̃ḭ̃s̰̃h̰̃📉 📉📉📉 DIA’s Descent: Decoding the Dow’s Dramatic Downturn 📉📉📉 I’ll never forget my last half marathon. It wasn’t a run, I speedwalked the whole thing, all 21 kilometres (13.1 miles), for a charity close to my heart. By the 19 kilometre mark, my legs were screaming, my breath was ragged, and the finish line felt like a cruel mirage. I’d poured everything into it, pushing past the cheers and the exhaustion, until I hit my limit and stumbled. That’s where I see the Dow Jones Industrial Average ETF ($DIA) right now, sitting at $415.50 as of 29 March 2025. After a 15-year climb, it’s wobbling, and its chart is whispering, or maybe shouting, that a drop is coming by October. Let me wa","listText":"<a href=\"https://ttm.financial/S/DIA\">$SPDR Dow Jones Industrial Average ETF Trust(DIA)$</a> b̰̃ḛ̃ã̰r̰̃ḭ̃s̰̃h̰̃📉 📉📉📉 DIA’s Descent: Decoding the Dow’s Dramatic Downturn 📉📉📉 I’ll never forget my last half marathon. It wasn’t a run, I speedwalked the whole thing, all 21 kilometres (13.1 miles), for a charity close to my heart. By the 19 kilometre mark, my legs were screaming, my breath was ragged, and the finish line felt like a cruel mirage. I’d poured everything into it, pushing past the cheers and the exhaustion, until I hit my limit and stumbled. That’s where I see the Dow Jones Industrial Average ETF ($DIA) right now, sitting at $415.50 as of 29 March 2025. After a 15-year climb, it’s wobbling, and its chart is whispering, or maybe shouting, that a drop is coming by October. Let me wa","text":"$SPDR Dow Jones Industrial Average ETF Trust(DIA)$ b̰̃ḛ̃ã̰r̰̃ḭ̃s̰̃h̰̃📉 📉📉📉 DIA’s Descent: Decoding the Dow’s Dramatic Downturn 📉📉📉 I’ll never forget my last half marathon. It wasn’t a run, I speedwalked the whole thing, all 21 kilometres (13.1 miles), for a charity close to my heart. By the 19 kilometre mark, my legs were screaming, my breath was ragged, and the finish line felt like a cruel mirage. I’d poured everything into it, pushing past the cheers and the exhaustion, until I hit my limit and stumbled. That’s where I see the Dow Jones Industrial Average ETF ($DIA) right now, sitting at $415.50 as of 29 March 2025. After a 15-year climb, it’s wobbling, and its chart is whispering, or maybe shouting, that a drop is coming by October. Let me wa","images":[{"img":"https://community-static.tradeup.com/news/d4f445872d62ce4ae1cbb23c437cd94e","width":"1024","height":"1536"},{"img":"https://community-static.tradeup.com/news/66cae8161217079c3fe174546f347d4d","width":"1170","height":"2715"},{"img":"https://community-static.tradeup.com/news/6eacdb880745b4778a46687b9d5e072d","width":"1521","height":"935"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/418580862959912","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":418933923442904,"gmtCreate":1743278449868,"gmtModify":1743278453830,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a>&nbsp;","text":"$Tesla Motors(TSLA)$","images":[{"img":"https://community-static.tradeup.com/news/6b80f01423d04f074468812ceb2e4f67","width":"1080","height":"2926"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/418933923442904","isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":421179302179144,"gmtCreate":1743810240798,"gmtModify":1743810243450,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;[Cool]&nbsp;&nbsp;[Cool]&nbsp;&nbsp;[Cry]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;[Cool]&nbsp;&nbsp;[Cool]&nbsp;&nbsp;[Cry]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;[Tongue]&nbsp;&nbsp;","text":"$NVIDIA(NVDA)$ [Cool] [Cool] [Cry] [Tongue] [Tongue] [Tongue] [Tongue]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421179302179144","isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":421132676587760,"gmtCreate":1743797846362,"gmtModify":1743797850024,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/.DJI\">$Dow Jones(.DJI)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/.IXIC\">$NASDAQ(.IXIC)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/.DJI\">$Dow Jones(.DJI)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp;","text":"$NASDAQ(.IXIC)$ $Dow Jones(.DJI)$","images":[{"img":"https://community-static.tradeup.com/news/84b4e25e424aed52934f3994fed44b31","width":"968","height":"1361"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/421132676587760","isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":420895970975912,"gmtCreate":1743788990762,"gmtModify":1743788992955,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420895970975912","repostId":"2524324922","repostType":2,"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420891798364360,"gmtCreate":1743759127180,"gmtModify":1743759440100,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"Join me on Tiger Trade！","htmlText":"Find out more here:<a href=\"https://tigr.link/s/10AoVhe\">Join me on Tiger Trade！</a> Enjoy ZERO fees when trading 23,000+ US and ASX stocks! Deposit to get AUD 30 cash voucher - AUD 20 as a welcome reward plus an extra AUD 10 referral bonus! Use my referral link, and we’ll both earn rewards! T&amp;Cs apply.","listText":"Find out more here:<a href=\"https://tigr.link/s/10AoVhe\">Join me on Tiger Trade！</a> Enjoy ZERO fees when trading 23,000+ US and ASX stocks! Deposit to get AUD 30 cash voucher - AUD 20 as a welcome reward plus an extra AUD 10 referral bonus! Use my referral link, and we’ll both earn rewards! T&amp;Cs apply.","text":"Find out more here:Join me on Tiger Trade！ Enjoy ZERO fees when trading 23,000+ US and ASX stocks! Deposit to get AUD 30 cash voucher - AUD 20 as a welcome reward plus an extra AUD 10 referral bonus! Use my referral link, and we’ll both earn rewards! T&Cs apply.","images":[{"img":"https://static.tigerbbs.com/0982a70a961bc5c3ec36a93070c46f6a"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/420891798364360","isVote":1,"tweetType":1,"viewCount":3,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":418178938970320,"gmtCreate":1743090360345,"gmtModify":1743090362042,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/418178938970320","repostId":"1153254691","repostType":4,"isVote":1,"tweetType":1,"viewCount":75,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420955695476936,"gmtCreate":1743774727061,"gmtModify":1743774729209,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420955695476936","repostId":"420251431379040","repostType":1,"repost":{"id":420251431379040,"gmtCreate":1743631190512,"gmtModify":1743687002669,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3559581955535845","idStr":"3559581955535845"},"themes":[],"title":"Say Hello To China's Terrific 10, Forget The Magnificent 7? ","htmlText":"🌟🌟🌟China's Terrific 10 are performing well in recent times,&nbsp; not the Magnificent 7.&nbsp; Shall we focus on China's Terrific 10 and not the Magnificent 7? For those who are new to investing, the Terrific 10 are Alibaba, Tencent, Meituan, Xiaomi, JD.com, NetEase, Baidu, BYD, Geely and SMIC.&nbsp; &nbsp;&nbsp; The Magnificent 7 represents 7 of US' strongest Tech Stocks - Apple, Microsoft, Nvidia&nbsp;Amazon, Alphabet, Meta Platforms and Tesla. The Magnificent 7 performed well in 2024 but in 2025,&nbsp; &nbsp;performance for these mega cap stocks has been mostly negative so far. It all began with the emergence of cheaper AI technology developed by DeepSeek which may have&nbsp;&nbsp;kick start a new wave of AI investment in China.&nbsp; DeepSeek has shown the way that it is possible to ac","listText":"🌟🌟🌟China's Terrific 10 are performing well in recent times,&nbsp; not the Magnificent 7.&nbsp; Shall we focus on China's Terrific 10 and not the Magnificent 7? For those who are new to investing, the Terrific 10 are Alibaba, Tencent, Meituan, Xiaomi, JD.com, NetEase, Baidu, BYD, Geely and SMIC.&nbsp; &nbsp;&nbsp; The Magnificent 7 represents 7 of US' strongest Tech Stocks - Apple, Microsoft, Nvidia&nbsp;Amazon, Alphabet, Meta Platforms and Tesla. The Magnificent 7 performed well in 2024 but in 2025,&nbsp; &nbsp;performance for these mega cap stocks has been mostly negative so far. It all began with the emergence of cheaper AI technology developed by DeepSeek which may have&nbsp;&nbsp;kick start a new wave of AI investment in China.&nbsp; DeepSeek has shown the way that it is possible to ac","text":"🌟🌟🌟China's Terrific 10 are performing well in recent times, not the Magnificent 7. Shall we focus on China's Terrific 10 and not the Magnificent 7? For those who are new to investing, the Terrific 10 are Alibaba, Tencent, Meituan, Xiaomi, JD.com, NetEase, Baidu, BYD, Geely and SMIC. The Magnificent 7 represents 7 of US' strongest Tech Stocks - Apple, Microsoft, Nvidia Amazon, Alphabet, Meta Platforms and Tesla. The Magnificent 7 performed well in 2024 but in 2025, performance for these mega cap stocks has been mostly negative so far. It all began with the emergence of cheaper AI technology developed by DeepSeek which may have kick start a new wave of AI investment in China. DeepSeek has shown the way that it is possible to ac","images":[{"img":"https://community-static.tradeup.com/news/b64d61f5df8d2b990cf0b63fff8496f7","width":"1080","height":"2340"},{"img":"https://community-static.tradeup.com/news/886748475219af837286c8e0c48b2e33","width":"1080","height":"2340"},{"img":"https://community-static.tradeup.com/news/471136558f5506bacde04e2d166fe1bf","width":"1080","height":"2340"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420251431379040","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420328375668952,"gmtCreate":1743649879854,"gmtModify":1743650176817,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OZXX.AU\">$GLOBAL X AU EX FINRES ETF(OZXX.AU)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/OZXX.AU\">$GLOBAL X AU EX FINRES ETF(OZXX.AU)$ </a>&nbsp;","text":"$GLOBAL X AU EX FINRES ETF(OZXX.AU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420328375668952","isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420326954156256,"gmtCreate":1743649806786,"gmtModify":1743649810959,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OZXX.AU\">$GLOBAL X AU EX FINRES ETF(OZXX.AU)$ </a> þt9","listText":"<a href=\"https://ttm.financial/S/OZXX.AU\">$GLOBAL X AU EX FINRES ETF(OZXX.AU)$ </a> þt9","text":"$GLOBAL X AU EX FINRES ETF(OZXX.AU)$ þt9","images":[{"img":"https://community-static.tradeup.com/news/0c17f0c1efbbacc95bddc0c545024821","width":"1080","height":"2885"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420326954156256","isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":420327027257560,"gmtCreate":1743649550652,"gmtModify":1743649556061,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"81db26a3675042e4bf1329fb7d2200a3","htmlText":"Find out more here:<a href=\"https://tigr.link/s/90Anrh0\">81db26a3675042e4bf1329fb7d2200a3</a>","listText":"Find out more here:<a href=\"https://tigr.link/s/90Anrh0\">81db26a3675042e4bf1329fb7d2200a3</a>","text":"Find out more here:81db26a3675042e4bf1329fb7d2200a3","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420327027257560","isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420285845058144,"gmtCreate":1743639872012,"gmtModify":1743639876943,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"US STOCK OPTION QUOTES","htmlText":"Find out more here:<a href=\"https://tigr.link/s/40AniEJ\">US STOCK OPTION QUOTES</a> null","listText":"Find out more here:<a href=\"https://tigr.link/s/40AniEJ\">US STOCK OPTION QUOTES</a> null","text":"Find out more here:US STOCK OPTION QUOTES null","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420285845058144","isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":420285756469304,"gmtCreate":1743639662776,"gmtModify":1743642207114,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"Help Center - Tiger Brokers","htmlText":"Find out more here:<a href=\"https://tigr.link/s/50AniAy\">Help Center - Tiger Brokers</a> Tiger Brokers is a company listed on NASDAQ. With U.S. licenses, it has become the platform of choice for global Chinese investors to trade in the U.S. and Hong Kong. Investors can easily open accounts online with Tiger Brokers.","listText":"Find out more here:<a href=\"https://tigr.link/s/50AniAy\">Help Center - Tiger Brokers</a> Tiger Brokers is a company listed on NASDAQ. With U.S. licenses, it has become the platform of choice for global Chinese investors to trade in the U.S. and Hong Kong. Investors can easily open accounts online with Tiger Brokers.","text":"Find out more here:Help Center - Tiger Brokers Tiger Brokers is a company listed on NASDAQ. With U.S. licenses, it has become the platform of choice for global Chinese investors to trade in the U.S. and Hong Kong. Investors can easily open accounts online with Tiger Brokers.","images":[{"img":"https://static.tigerbbs.com/ff98eccfaff055c5a7c86bee57069e0c"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420285756469304","isVote":1,"tweetType":1,"viewCount":11,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":420219988103192,"gmtCreate":1743623604364,"gmtModify":1743630108119,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"An Invitation Letter from Tiger Brokers","htmlText":"Find out more here:<a href=\"https://tigr.link/s/10AnaEz\">An Invitation Letter from Tiger Brokers</a> I have won a lot of awards in Tiger Brokers, come and see what rewards you have!","listText":"Find out more here:<a href=\"https://tigr.link/s/10AnaEz\">An Invitation Letter from Tiger Brokers</a> I have won a lot of awards in Tiger Brokers, come and see what rewards you have!","text":"Find out more here:An Invitation Letter from Tiger Brokers I have won a lot of awards in Tiger Brokers, come and see what rewards you have!","images":[{"img":"https://static.tigerbbs.com/ff98eccfaff055c5a7c86bee57069e0c"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420219988103192","isVote":1,"tweetType":1,"viewCount":43,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":420218802504112,"gmtCreate":1743623504138,"gmtModify":1743623508245,"author":{"id":"4206112858455532","authorId":"4206112858455532","name":"jazza","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4206112858455532","idStr":"4206112858455532"},"themes":[],"title":"US STOCK OPTION QUOTES","htmlText":"Find out more here:<a href=\"https://tigr.link/s/20AnXfl\">US STOCK OPTION QUOTES</a> null","listText":"Find out more here:<a href=\"https://tigr.link/s/20AnXfl\">US STOCK OPTION QUOTES</a> null","text":"Find out more here:US STOCK OPTION QUOTES null","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/420218802504112","isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}